Absolute quantification of transcription factors during cellular differentiation using multiplexed targeted proteomics by Simicevic, Jovan et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2013
Absolute quantification of transcription factors during cellular differentiation
using multiplexed targeted proteomics
Simicevic, Jovan; Schmid, Adrien W; Gilardoni, Paola A; Zoller, Benjamin; Raghav, Sunil K; Krier,
Irina; Gubelmann, Carinne; Lisacek, Frédérique; Naef, Felix; Moniatte, Marc; Deplancke, Bart
Abstract: The cellular abundance of transcription factors (TFs) is an important determinant of their
regulatory activities. Deriving TF copy numbers is therefore crucial to understanding how these proteins
control gene expression. We describe a sensitive selected reaction monitoring–based mass spectrometry
assay that allowed us to determine the copy numbers of up to ten proteins simultaneously. We applied
this approach to profile the absolute levels of key TFs, including PPAR￿ and RXR￿, during terminal
differentiation of mouse 3T3-L1 pre-adipocytes. Our analyses revealed that individual TF abundance
differs dramatically (from 250 to >300,000 copies per nucleus) and that their dynamic range during
differentiation can vary up to fivefold. We also formulated a DNnA binding model for PPAR￿ based
on TF copy number, binding energetics and local chromatin state. This model explains the increase in
PPAR￿ binding sites during the final differentiation stage that occurs despite a concurrent saturation in
PPAR￿ copy number.
DOI: 10.1038/nmeth.2441
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-78970
Originally published at:
Simicevic, Jovan; Schmid, Adrien W; Gilardoni, Paola A; Zoller, Benjamin; Raghav, Sunil K; Krier,
Irina; Gubelmann, Carinne; Lisacek, Frédérique; Naef, Felix; Moniatte, Marc; Deplancke, Bart (2013).
Absolute quantification of transcription factors during cellular differentiation using multiplexed targeted
proteomics. Nature Methods, 10(6):570-576. DOI: 10.1038/nmeth.2441
Absolute quantification of transcription factors during 
cellular differentiation using multiplexed targeted 
proteomics 
 
Jovan Simicevic1,5, Adrien W. Schmid2,5, Paola A. Gilardoni1,5, Benjamin Zoller3, Sunil 
K. Raghav1, Irina Krier1, Carine Gubelmann1, Frédérique Lisacek4, Felix Naef3, Marc 
Moniatte2,*, Bart Deplancke1,* 
 
1Laboratory of Systems Biology and Genetics, Institute of Bioengineering, School of 
Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), CH-1015 
Lausanne, Switzerland 
2 Proteomics Core Facility, School of Life Sciences, Ecole Polytechnique Fédérale de 
Lausanne (EPFL), CH-1015 Lausanne, Switzerland 
3 Laboratory of Computational Systems Biology, Institute of Bioengineering, School of 
Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), CH-1015 
Lausanne, Switzerland 
4SIB Swiss Institute of Bioinformatics, Geneva, Switzerland 
5These authors contributed equally to this work 
 
*Corresponding authors:  
Marc Moniatte 
EPFL Proteomics Core Facility 
EPFL-PCF-PTP, Station 15 
CH-1015 Lausanne 
Tel: +41 (0)21 693 17 53 
Fax: +41 (0)21 693 18 88 
E–mail: marc.moniatte@epfl.ch 
 
 
Bart Deplancke 
Laboratory of Systems Biology and Genetics (LSBG) 
EPFL-SV-IBI-LBSG, Station 19 
CH-1015 Lausanne 
Tel: +41 (0)21 693 18 21 
Fax: +41 (0)21 693 09 80 
Email: bart.deplancke@epfl.ch 
  
2 
 
Abstract 
The regulatory properties of transcription factors (TFs) are largely dictated by their 
cellular abundance. Deriving absolute TF copy numbers is therefore crucial to 
understand how these proteins control gene expression. Here, we implement a 
sensitive selected reaction monitoring (SRM)-based mass spectrometry assay, 
allowing us to simultaneously determine the copy numbers of up to 10 proteins. We 
apply this approach to profile the levels of key TFs during terminal differentiation of 
mouse 3T3-L1 pre-adipocytes, revealing that TF abundance differs dramatically (from 
~250 to >300,000 copies per nucleus), but that their dynamic range during 
differentiation varies at most five-fold. We also formulate a genome-wide TF DNA 
binding model to explain the significant increase in binding sites of the adipogenic 
master regulator PPARγ during the final differentiation stage, despite a concurrent 
saturation in PPARγ copy number. This model provides unique, quantitative insights 
into the relative contributions of binding energetics, copy number, and chromatin 
state in dictating TF DNA occupancy profiles. 
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Introduction 
Differential gene expression is controlled by gene regulatory networks, which consist 
of functional interactions between regulatory state (e.g. transcription factors (TFs) 
and genomic (e.g. gene promoters, enhancers) components1. A major current 
interest is to derive models of gene regulatory networks that elucidate or predict the 
dynamic transcriptional mechanisms underlying complex gene expression programs2-
4. An important drawback of existing models is that relatively little quantitative data 
has so far been used in their calibration. In particular, accurate measurements on the 
absolute, molecular abundance of most TFs are still very sparse2, even though such 
information is key to understand most biochemical and regulatory processes 
involving this type of proteins5, 6. This conundrum can be explained by the relatively 
low expression of TFs in cells7, which make their direct quantification or that of any 
other low abundant protein by mass spectrometry (MS) or other assays a substantial 
challenge. 
Newly emerging proteomic approaches combining selected reaction 
monitoring (SRM) or high resolution MS with isotope dilution quantification strategies 
now promise to alleviate this scarcity in copy number data as they enable quantitative 
analyses over a wide concentration range8-10. These approaches all share the same 
principle of targeting a subset of detectable peptides, which are specific to the protein 
of interest (proteotypic peptides)11. Quantification is then achieved by comparing their 
extracted MS signals to those of accurately quantified, isotopically-labeled peptides, 
which are used as internal standards8. These peptides can be produced 
synthetically8 or are now increasingly being derived from the proteolysis of full-length 
proteins that are themselves recombinantly12-16 expressed or synthetically derived17. 
This is because the use of isotopically labeled full-length proteins offers clear 
advantages over other recently developed quantification approaches (a comparative 
overview of these approaches is shown in Supplementary Table 1). Both synthetic- 
and recombinant-based approaches offer the possibility of introducing single 
reference (e.g. 16-19) or solubility (e.g. albumin binding protein15 or glutathione-S-
transferase14) tags linked to parent proteins. This enables the stoichiometric 
quantification of peptide standards released upon protein digestion, which are then 
used to quantify the endogenous protein within a complex sample. However, despite 
their potential in deriving accurate protein copy number measurements, particularly 
for low abundant proteins, only a few studies incorporating such targeted MS 
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approaches have so far demonstrated their capacity to accurately measure copy 
numbers of TFs in higher eukaryotes14, 15. In addition, none of these studies were to 
our knowledge specifically optimized to tackle the difficult task of monitoring the 
dynamic expression of TFs over the course of specific biological processes. 
Furthermore, currently available approaches typically rely on the use of a single 
reference peptide or tag which is spiked early in the analytical process. While the 
latter corrects for the concomitant loss in endogenous peptides during sample 
digestion and fractionation and thus increases accuracy and reproducibility20, 21, the 
use of only one reference tag requires that the quantification of each protein standard 
is accomplished separately. This ultimately adds avoidable steps into the workflow 
potentially introducing undesirable artifacts (Supplementary Table 1). 
These collective considerations prompted us to develop an SRM-based 
workflow, specifically tailored around the quantification of more lowly abundant 
proteins such as TFs, in which the internal protein standard quantification step is 
entirely performed in situ (i.e. the protein standard and its endogenous counterpart 
are simultaneously quantified). Here, we applied this workflow to assess the dynamic 
changes in absolute TF levels during the terminal phase of adipogenesis. While 
quantitative proteomic studies have been performed to explore the adipogenic 
proteome, these lacked the required sensitivity to detect and quantify even core 
adipogenic master regulators such as PPARγ and RXRα22, 23, illustrating the inherent 
complexity of targeting TFs23. 
 
Results 
Selection of TF-specific transitions for targeted SRM  
The selection of proteotypic peptides for TFs proved challenging, mainly due to data 
scarcity in public repositories and to difficulties in detecting tryptic peptides in 
discovery experiments (Supplementary Fig. 1 and Online Methods). We therefore 
decided to adopt an in vitro full-length protein expression-based strategy to derive 
proteotypic peptides, which allows for a better accounting of the local environment 
surrounding the peptide cleavage sites (Online Methods and data not shown). Ten 
TFs (including PPARγ and RXRα) that are expressed during terminal adipogenesis 
were selected after which the corresponding recombinant proteins were tagged with 
C-terminal glutathione S-transferase (GST) for full-length expression validation and 
purification (Supplementary Table 2 and Supplementary Fig. 2). In-gel separation 
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followed by high resolution LC-MS/MS on the tagged TF-containing fraction then 
enabled us to generate a collection of experimentally detected TF-specific tryptic 
peptides for the 10 proteins (Supplementary Data 1 and Online Methods).  
 
Implementation of the SRM-based methodology 
Given the benefits of using full-length proteins as standards over other sources12, 24 
(Supplementary Table 1), we set out to utilize isotopically-labeled, in vitro-
expressed TFs directly as standards for quantification of their endogenous 
counterparts. Building on pioneering work18, 19, 25, we implemented a modified version 
of the same workflow that we have adopted for transition selection. For this purpose, 
we aimed to add an in-frame proteotypic reference-peptide tag at the N–terminus of 
the protein constructs that should serve as surrogate during the quantification step. 
After having considered several possibilities18, 19 (Online Methods), we found that 
the SH-Quant peptide19 offers optimal solubility and stability properties 
(Supplementary Fig. 3). We therefore adopted it for the in situ quantification of 
heavy TFs utilizing a synthetic and accurately quantified light SH-Quant counterpart. 
In this manner, one single peptide only (the SH-Quant) is used for the absolute 
quantification of a heavy, in vitro-expressed standard TF, thus simplifying and 
reducing the cost of the assays even further. In turn, quantification of the 
endogenous TF in absolute amounts is achieved by utilizing TF-specific peptides 
(Fig. 1a-b). 
 
Absolute quantification of PPARγ and RXRα 
To evaluate PPARγ and RXRα peptide transitions, two separate pilot SRM assays 
were implemented as depicted in Fig. 1a and exemplified in Fig. 1b-c (details in 
Supplementary Figs. 4-6). Subsequently, the complete workflow was applied to 
monitor the absolute, nuclear abundance of PPARγ and RXRα during terminal 
adipogenesis. The technical robustness of the whole workflow is highlighted by the 
low coefficient of variation (CV) obtained within one biological sample 
(Supplementary Fig. 7). The resulting data, as summarized in Fig. 2 and 
Supplementary Table 3, provide unique insights into the dynamic protein copy 
number per cell (nucleus) profiles of PPARγ and RXRα.  
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To corroborate our results and to provide an independent assessment of the 
accuracy of our method, we performed three validation experiments. First, we 
performed Western blot analysis for each time-point (Supplementary Fig. 8 and 
Online Methods), revealing that the detected TF abundance profiles mirror those 
observed by our SRM-based quantification approach. To provide a more quantitative 
assessment of the validity of our data, we performed semi-quantitative Western 
blotting on RXRα. Given the unavailability of purified mouse RXRα, we generated a 
calibration curve utilizing SRM for the quantification of in vitro-expressed RXRα 
standard and used it for Western blot-based quantification of endogenous RXRα at 
different time points during terminal adipogenesis (see Supplementary Fig. 9a-b 
and Online Methods). The resulting data show a good correlation with the SRM-
based measurements (Supplementary Fig. 9c-d, R2 = 0.72), although we found that 
the Western analysis tends to inflate RXRα copy numbers as compared to SRM-
derived data.  
 To resolve this finding and due to the not truly independent nature of this 
experiment, we performed a second validation assay. For this purpose, we randomly 
selected and accurately quantified using the same workflow presented in Fig. 1a two 
human proteins of different molecular weight, α-synuclein (SYN, 14.5 kDa) and 
histidyl-tRNA synthetase (HARS, 57.4 kDa), to assess overall protein recovery. The 
HARS protein was selected as it falls within the molecular weight range of our TFs of 
interest, whereas SYN was selected to test the recovery of a significantly smaller 
protein. Each protein was spiked in amounts corresponding to 5,000 and 50,000 
copies per cell into nuclear extracts to mimic the concentration range observed for 
TFs as well as the experimental nucleic background proteome (Online Methods). 
Our SRM validation predicted 4,620 and 45,950 copies of HARS per cell 
corresponding to an overall protein recovery of ~92% for both (Supplementary Figs. 
10a-e and 11). Slightly lower numbers were obtained for SYN, showing a recovery 
ranging from 65% to 80% (Supplementary Figs. 10f and 11). This lower 
performance may be caused by several factors, although we suspect that its small 
size may have led to greater diffusion during the gel de- and re-hydration processes 
applied prior to digestion, resulting in greater protein loss.  
 Finally, to assess the impact of gel fractionation on the accuracy of our 
method, we performed a relatively straight-forward gel recovery experiment using 
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RXRα as reference protein (see Online Methods). As can be observed in 
Supplementary Fig. 12, we found that losses associated with sample processing 
were in the range of 30% for small protein amounts (<2.5 ng), whereas this improved 
to only ~8% when dealing with larger amounts. It is reasonable to conclude that 
absolute values obtained for the targeted TFs at different differentiation times should 
lie within the same error margin.  
 Together, these experiments provide a candid assessment of the precision of 
the presented SRM-based quantification approach, revealing a high accuracy for 
protein quantities above 2.5 ng based on the HARS and RXRα measurements. 
These values are in line with those reported in recent studies (e.g.15) and are thus 
consistent with what is considered an acceptable measurement inexactitude in the 
field. In addition, these experiments demonstrate that our pipeline is in principle 
applicable to any protein as long as it expresses well in vitro.  
 
A quantitative model of genome-wide TF DNA binding 
The availability of absolute protein copy number data allowed us to examine the 
relationship between the number of genome-wide DNA binding events and TF 
molecules. Using published RXRα and PPARγ ChIP-seq data26, we found that, until 
the fourth differentiation day, the number of TF molecules and corresponding binding 
events correlate well (R2 = 0.96 for PPARγ; R2 = 0.85 for RXRα; Supplementary Fig. 
13), and that in general, there are substantially more RXRα than PPARγ binding 
events consistent with their corresponding TF copy numbers. These high correlations 
indicate that ChIP-seq occupancy data likely reflect endogenous conditions rather 
than being the result of differences in antibody-mediated protein recoveries as 
previously hypothesized26. A striking discrepancy was however observed for day six 
as, compared to previous days, the number of RXRα and PPARγ binding events 
significantly increases (>three-fold for both TFs), whereas the number of TF 
molecules saturates or even decreases (Supplementary Fig. 13).  
To reconcile these findings and to possibly provide a first-principle and 
quantitative analysis of this phenomenon, we generated a quantitative model to 
predict the number of PPARγ binding events in the genome given a number of TF 
molecules, ChIP detection threshold, and genome accessibility maps (see 
Supplementary Note for more details). This model bears similarity to previous 
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thermodynamic models of protein-DNA interactions3, 27, 28, but also features some 
important differences, notably through the use of absolute TF levels instead of 
inferred protein concentration data and the focus on modeling DNA binding behavior 
over the course of a mammalian cellular differentiation process. To incorporate 
genome accessibility data into our model, we used published genome-wide data of 
the chromatin mark histone three lysine 27 mono-acetylation (H3K27Ac) for 
differentiation days zero, two, and six29, since this mark is enriched at active and thus 
accessible genomic regions. Consequently, we formulated the model to account for 
the distribution of specific and non-specific sites for PPARγ in H3K27Ac-enriched 
regions (Fig. 3a). To assess the DNA binding events at thermodynamic equilibrium, 
we assumed that all the PPARγ proteins were on the DNA at either specific or non-
specific sites, consistent with the consensus in the field that TFs tend to mostly reside 
on DNA in vivo6. For the sake of simplicity, we did not consider interactions with other 
TFs, or hindrance due to other proteins sitting on DNA (for a discussion on these 
topics, see Supplementary Note).  
The resulting model predicts the number of binding events given the number 
of PPARγ copies per cell (nucleus) for each time point as a function of the ChIP 
detection threshold expressed as percentage occupancy (or residency time) (Fig. 
3b). While it is difficult to precisely estimate the latter threshold, a survey of our own 
and published ChIP data revealed that the signal associated with DNA binding is 
typically considered as positive from around 1% (as compared to input)30, 31. 
Interestingly, when we used ~1% as detection threshold, our model predicts binding 
event numbers which closely mimic the experimentally derived data (Fig. 3c). Thus, 
the model correctly predicts the temporal pattern in the number of binding sites over 
the course of terminal adipogenesis.  
As an independent test, we also repeated our analyses using another PPARγ 
ChIP-seq data set32, which yielded similar conclusions (Supplementary Note). A 
closer look into the determining factors revealed that the sharp increase in binding 
events at day six as compared to days zero and two is in part driven by the increase 
in PPARγ copy number between days two and six. However, we found that an 
equally important factor relates to shifts in the relative distributions of higher versus 
lower affinity sites in accessible genomic regions at the different differentiation time 
points (Fig. 3a). Specifically, whereas the overall size of accessible regions is similar 
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across all days, we found that cells undergo important chromatin remodeling between 
days six as compared to zero and two such that more medium-to-high affinity sites 
for PPARγ become available. This in turn allows for a substantial increase in 
detectable DNA binding events even though the TF copy number increase is 
relatively modest. Together, these analyses show the value of accurately quantifying 
TF copy numbers to generate quantitative DNA binding models from which emergent 
properties regarding gene regulatory mechanisms underlying a specific biological 
process can be derived. 
 
Multiplexing the SRM assay 
Next, we sought to overcome the current limitation of quantifying only one protein per 
assay. For this purpose, we designed nine quantotypic SH-Quant tag variants that, 
along with the original SH-Quant tag, allow the quantification of up to 10 proteins or 
TFs in one single integrated SRM assay. We subsequently generated 10 expression 
vectors enabling the coupling of each tag variant to a distinct, adipogenic TF (among 
which we also included PPARγ and RXRα as validation). Corresponding transitions 
as well as the retention time of the parent ions are presented in Fig. 4a. The 
performance as well as chromatographic separation of the nine, newly designed 
candidates and their parent SH-Quant sequence was tested in a series of SRM runs 
(Fig. 4a-e). Two SH-Quant tag-variants “AADITSLYK” and “AAEVTSLYK” are 
isobaric and yet could be clearly distinguished by their chromatographic profile and 
by their distinct transitions (Fig. 4b-e). A standard curve was established for each 
SH-Quant tag variant by spiking them into the same 3T3-L1 nuclear extract 
preparation that was next used for TF abundance measurements (Supplementary 
Figs. 14 and 15). This allowed us to determine the lower limit of quantification 
(LLOQ) for each tag (Supplementary Fig. 16). Applying the multiplex version of our 
methodology, we were able to monitor endogenous levels of 10 TFs 
(Supplementary Table 2) in 3T3-L1 nuclear extracts derived from three terminal 
differentiation time points (Day 0, Day 2, and Day 4) (Fig. 5a-b). As summarized in 
Fig. 5c and Supplementary Fig. 17, we found that the majority of the additionally 
analyzed TFs (e.g. PIAS4, NFIB, SMAD2, RARγ, FOSL2) are expressed within 
approximately the same copy number range as PPARγ or RXRα (Supplementary 
Table 3). Importantly, measurements of PPARγ and RXRα copy numbers were 
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coherent with data obtained with the non-multiplex approach, indicating that the up-
scaling of the SRM assay does not interfere with measurement precision. The 
abundance of other TFs such as PIAS3, NR2C1, and ARID3a fell below the 
quantification threshold. Nevertheless, the overall quality of the fragment ions 
monitored for the heavy and light peptides (Supplementary Fig. 18) clearly allows 
for the unambiguous identification of these TFs.  
 
Discussion  
Determining the copy number of TFs has been of longstanding interest given that the 
DNA binding ability of a TF and hence its regulatory capacity strongly depends on its 
cellular concentration5, 6. However, despite the fundamental importance of TFs in 
most biological processes, a recent survey showed that the number of studies that 
have so far provided estimates on the abundance of animal TFs is low (~25)6. These 
estimates were moreover mostly achieved with indirect immuno-based measuring 
methods whose additional drawback is the dependence on antibodies which are 
available for only a low number of TFs. Nevertheless, these studies estimated TFs to 
be expressed in the range of 5,000 to several hundred thousand copies per nucleus6 
in line with our results. 
To increase our understanding of TF behavior and to circumvent the issues 
typically encountered with immuno-based methods, we developed an SRM-based 
workflow which affords sufficient sensitivity and analytical reproducibility to generate 
quantitative data in absolute terms. This workflow offers several advantages: 
First, the only requisite of our SRM-based assay is the relatively straight-
forward in vitro expression of the protein candidate, which, except for certain types of 
proteins, becomes relatively trivial given the availability of efficient cloning and 
expression systems and Open-Reading Frame (ORF) clone libraries33, 34. Having 
easy access to the full-length protein has thereby the advantage of facilitating the 
empirical selection of the best quantotypic peptides for protein types that may not be 
well represented in spectral library databases (such as TFs). In addition, the ability to 
nearly extemporaneously produce heavy-labeled full-length protein standards, and to 
simultaneously quantify these protein standards and their endogenous counterparts 
within the same assay bypasses another significant source of variability in any 
quantitative assay, namely the necessity for protein/peptide storage24.  
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Second, the assay is pillared on the use of the quantotypic SH-Quant reporter 
peptide which was found to feature high digestability, excellent solubility, ionisability 
and stability, and thus to exhibit optimal peptide properties for the robust and 
accurate quantification of proteins. Importantly, the SH-Quant tag allowed the design 
of tag variants with very similar properties enabling the in situ analysis of multiple 
proteins in one single assay in robust, sensitive, and reproducible fashion. So far, we 
have deliberately limited the number of TFs that are simultaneously quantified in situ 
for this assay. This is because we found that further multiplexing may jeopardize the 
overall sensitivity of the assay as the latter was specifically conceived to 
accommodate such throughput in the context of quantifying TFs. However, our 
approach is in principle not limited to 10 target proteins, providing that additional 
quantotypic tags are designed and validated and that the same overall accuracy and 
sensitivity compared to the “one protein at a time” approach is maintained. Together, 
we believe that our quantification strategy constitutes a powerful alternative to 
quantitative immunoassays (immunoblotting or ELISA) to determine fluctuations in 
protein abundance over a wide concentration range with the additional advantages 
over such assays of being able to multiplex and being independent of protein-specific 
antibodies35. This multiplex capacity should be of great value to those interested in 
examining or modeling absolute, dynamic changes of entire pathways or sets of 
biomarkers of interest in wildtype versus clinical, disease, or perturbation settings.  
Here, we illustrate the importance of deriving this type of data by building a 
quantitative model aiming to clarify an intriguing discrepancy between TF binding site 
and copy number data. As such, we provide a quantitative explanation for the 
common observation that many TFs, including PPARγ, bind to significantly fewer 
sites in the genome than predicted based on the presence of their respective 
consensus motifs29, 36, 37. Whereas it was suggested that other factors may contribute 
to this binding site selectivity, here, we demonstrate that, at least for PPARγ, its DNA 
binding profile can be closely modeled by simply considering its own copy number, 
simple thermodynamic principles, and chromatin accessibility. The functional 
consequence of our findings is that the chromatin state constitutes a landing map for 
PPARγ DNA binding, consistent with the emerging notion of the importance of 
chromatin structure in shaping TF DNA binding patterns37.  
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Figures 
 
Figure 1: Workflow for the absolute quantification of TFs in 3T3-L1 cells. 
(a) The left panel shows the preparation of 3T3-L1 total nuclear protein extract (NE). 
Cells are lysed at the indicated differentiation time point (Day0 (D0) to Day 6 (D6)) 
after which nuclear proteins are extracted. The resulting protein mixture is separated 
by SDS-PAGE and bands at the migration height of TF’s are excised from the gel. 
The far right column depicts the preparation of in vitro-expressed SH-tagged TFs. 
The constructs are expressed in their heavy-labeled version (*) using a wheat germ-
based in vitro transcription-translation kit, purified by GST affinity and separated by 
SDS-PAGE. Bands containing the heavy-labeled constructs, here SH-RXRα-GST*, 
are excised from the gel. Each nuclear extract band to be quantified is mixed with a 
gel slice of the in vitro-expressed TF construct, spiked with known amounts of light 
SH-Quant tag (center), and in-gel digested together. The resulting peptide mixtures 
are then quantified by SRM using validated proteotypic peptides selected from 
information previously collected on each in vitro-expressed TF via shotgun-MS runs. 
Each TF quantification requires a separate experiment in this configuration. (b) A 
schematic presentation of the quantitation approach as outlined in (a). (c) i. RXRα 
protein sequence with its highlighted tryptic peptides sequences used for 
quantitation. ii. SRM chromatogram of the five RXRα proteotypic fragments and its 
SH-Quant tag. iii. Zoom of the SH-Quant peptide in its light and heavy isoform and 
the Pinpoint software calculated curves for both isoforms (iv). 
 
Figure 2. Summary of RXRα and PPARγ levels quantified by SRM. 
(a) A graphical summary of the RXRα (left) and PPARγ (right) concentrations, 
expressed as fmol µg–1 nuclear extract (NE), in three individual biological replicates. 
(b) Absolute RXRα and PPARγ levels visualized as copies per cell. The bars 
represent the mean ± s.e.m of three biological replicates (n=3).  
 
Figure 3. Quantitative modeling of genome-wide PPARγ DNA binding. 
(a) Cumulative number of genomic sites in H3K27Ac regions at Day 0 (gray line), 
Day 2 (dashed line), and Day 6 (black line). The axis runs from the strongest, i.e. 
1000-fold stronger than non-specific sites, to medium affinity sites, i.e. 60-fold 
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stronger. While the numbers for Day 0 and Day 2 are comparable, Day 6 shows a 
35% increase in this range. (b) Number of detected bound loci at Day 0 (gray line), 
Day 2 (dashed line), and Day 6 (black line) during 3T3-L1 terminal differentiation in 
function of the detection threshold on the expected occupancy. The model takes into 
account the measured PPARγ copies per cell (nucleus) and the distribution of 
accessible high affinity sites. Matching with the number of experimentally derived 
PPARγ ChIP-seq sites predicts an occupancy threshold of 1.35%. (c) Temporal 
pattern for the predicted number of detected PPARγ-bound sites (dashed line), the 
actual number of measured sites (black line), and the protein copy number (grey 
line). Note that the number of sites shows an exponential-like increase, while the 
protein copy number graph reflects saturation. 
 
Figure 4. Properties of the SH-Quant tag variants. 
(a) The table provides a detailed summary of the different peptide-tags specifically 
designed for the multiplex assay. The amino acid sequences of tags 2 through 10 
were derived from the original SH-Quant tag (1), and were designed with the intent of 
conserving intense y” fragment ions at positions y2 to y5 for quantification purposes. 
The fragmentation fingerprint of modified ions y6 to y8 allows for improved tag 
identification, particularly when dealing with isobaric peptides. This specific peptide 
design allows for a clear LC separation of the isobaric tags: 3 versus 7 (m/z = 470.2; 
green), and 1 versus 9 (m/z = 491.2; red). (b) LC-SRM chromatogram showing the 
extent of separation of the peaks belonging to the SH-Quant peptide-variants; proper 
separation was achieved for most tags using a short LC gradient of 60 min. (c) LC-
SRM chromatogram of a multiplexed nuclear extract sample using a 120 minute 
gradient. (d) Zoom-in view of the area highlighted in panel c), showing the extracted 
ion current (EIC) of isobaric SH-Quant tags 1 and 9 in a multiplex sample (peak 1: 
m/z = 491.2, peak 2: m/z = 491.2). (e) Calculation of the peak areas of the light and 
heavy peptide counterparts using Pinpoint. The difference in physicochemical 
properties of two isobaric SH-Quant tags 9 and 1 result in separate elution times, 
30.7 min (AAEVTSLYK) and 35 min (AADITSLYK) respectively. Identical elution 
times were observed for both light and heavy counterparts in all 10 SH-Quant tags. 
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Figure 5. Simultaneous monitoring of the nuclear abundance of ten TFs during 
terminal adipogenesis via spiking of in vitro-expressed full-length TFs. 
(a) Multiplex SRM transition profiles of selected best-responding tryptic peptides from 
all ten TFs (light and heavy) during a 120 minute LC-SRM run. (b) Zoom-in (minutes 
29-36) of the highlighted region in spectrum (a), illustrating the complexity of the 
mixture and the separation quality achieved with the multiplex SRM assay on nuclear 
extract sample. (c) Calculated endogenous levels of all ten TFs detected at Day 0, 
Day 2, and Day 4 (bars represent the mean ± s.e.m of 4-6 technical replicates (n=4-
6)).   
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Online Methods 
 
3T3-L1 cell culture, differentiation, and protein extraction 
3T3-L1 cells were cultured and differentiated into adipocytes as detailed in Raghav et 
al.,31. Briefly, 3T3-L1 cells were collected at six different differentiation time points 
(0h, 2h, Day 1, Day 2, Day 4, and Day 6). At each time-point, petri-plates were rinsed 
twice with 1X PBS, after which cells were trypsinized, rinsed once with cold 1X PBS, 
and centrifuged and the pellets were then stored at –80°C. Cells were lysed in cold 
lysis buffer (10mM HEPES-NaOH at pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 1 mM DTT, 
0.5% NP-40, 0.1 mM EDTA, 0.1 mM EGTA) containing protease inhibitors and 
phosphates inhibitors (Roche) for 15 min and centrifuged for 10 min at 6,000 rpm (at 
4°C) to sediment the nuclei. The pellet was washed twice to remove non-nuclear 
particles. The isolated nuclei were then washed using protein extraction buffer 
(20 mM HEPES-NaOH at pH 7.9, 25% glycerol, 1.5 mM MgCl2, 420 mM NaCl, 
0.1 mM EDTA, 0.1 mM EGTA) after adding protease inhibitor and phosphatase 
inhibitor cocktail tablets (Roche) at 4°C for 30 min and centrifuged for 10 min at 
6,000 rpm (at 4°C). Protein concentration was measured for each time point utilizing 
the Quick Start Bradford Dye Reagent (Bio-Rad). The supernatant containing nuclear 
proteins was collected and stored at –80°C.  
 
Cloning and plasmids 
Mouse TF ORFs were cloned in Gateway format essentially as described earlier31, 34. 
To make the wheat germ (WG) in vitro transcription-translation expression system 
(Promega) compatible with the mouse TF ORF clones and to allow the purification of 
TFs, we modified the SP6 pF3A WG (BYDV) Flexi vector (Promega) to 
accommodate the Gateway reading frame A cassette (Invitrogen). A glutathione-S-
transferase (GST)-coding sequence containing a stop codon was subsequently 
incorporated in frame at the 3’-end of the second (i.e. 3’) Gateway site using standard 
cloning techniques. TFs were then subcloned from the Gateway entry clone level into 
this “in-house” modified pF3A-GST destination vector by standard Gateway cloning. 
 
In vitro protein expression and purification, gel staining, and immunoblotting 
For selection of optimal TF transitions: the 10 selected TFs containing a GST 
tag at their C-terminus were expressed in vitro via the TnT SP6 High Yield Wheat 
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Germ Protein Expression System (Promega) according to the manufacturer’s 
protocol. GST-labeled TFs were subsequently purified via glutathione sepharose 4B 
beads (GE Healthcare) and incubated overnight at 4°C on a rotator to enrich for the 
GST-fusion proteins. The beads were washed three times with a saline buffer 
(50 mM tris-HCl pH 8.0, 150 mM NaCl, 2mM EDTA, 0.1% NP-40, 10% glycerol) and 
boiled at 95°C for 5 min in protein loading buffer to release the fusion proteins. The 
protein-bead mixture was centrifuged at 6’000 rpm for 30 s to sediment the beads. 
The supernatant fraction was separated by SDS-PAGE in a 10% resolving gel (Tris-
Glycine) and stained either with silver nitrate or with Coomassie blue (SimplyBlue 
Safestain, Invitrogen) for band visualization. Validation of in vitro-expressed proteins 
was performed by Western blot using 1:2000 diluted rabbit anti-GST primary 
antibodies (Cell signalling) and 1:5000 diluted goat anti-rabbit coupled to HRP 
secondary antibodies (Santa Cruz) on a nitrocellulose membrane. Validation of 
PPARγ and RXRα expression was performed again by Western blotting using 1:500 
diluted rabbit anti-PPARγ (Santa Cruz, SC-7196) and 1:1000 diluted rabbit anti-RXRα 
(Santa Cruz, SC-553) primary antibodies, and using 1:1000 diluted PARP-1 as a 
nuclear control (Santa Cruz, SC-1561). Densitometric quantitation analyses were 
performed using the AlphaDigiDoc 1201 software (Alpha Innotech). (Semi)-
quantitative Western blotting: for RXRα standard curve generation, in vitro-expressed 
RXRα was purified as described above. An aliquot was subjected to SRM for 
quantification (see below), which aided in the generation of an RXRα dilution series 
(0.31-20 ng). The corresponding RXRα standard curve samples and 3T3-L1 nuclear 
extracts harvested at different time points during differentiation were then Western 
blotted as described above.. 
For TF quantification: the 10 selected TFs were expressed in vitro via the TnT 
SP6 Wheat Germ High Yield Master Mix Minus Amino Acids (Promega) in their 
isotopically-labeled version. 18 amino acids were mixed to reach a 80µM final 
concentration and added to the reaction together with isotopically-labeled Arginine 
(13C,15N-Arg) and Lysine (13C,15N-Lys)(Cambridge Isotope Laboratories) to a 1mM 
final concentration prior to resorting to the conventional expression protocol. 
Depending on the analyzed TF, 3X reactions were utilized (or 4X for TFs with low 
expression yields). Subsequently, the purification and fractionation techniques 
described above were applied.  
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Assessment of protein losses during gel extraction 
RXRα was in vitro-expressed and purified with glutathione sepharose 4B beads as 
described before. A series of dilutions (10 ng to 1.25 ng) was generated. One dilution 
set was used for validation by Western blotting using 1:1000 diluted rabbit anti-RXRα 
(Santa Cruz, SC-553) as described above. The second dilution set was loaded onto a 
10% SDS-PAGE, stained with Coomassie blue after which bands corresponding to 
RXRα were excised and in gel-digested (as describe earlier). To assess protein 
losses during in-gel digestion, the resulting RXRα samples were further quantified by 
SRM.  
 
Reference peptide tag incorporation 
SH-Quant quantification strategy: The SH-Quant peptide (AADITSLYK)-coding 
sequence along with the segment of the 5’ Gateway site comprised between the PvuI 
and PvuII restriction sites was synthesized by Geneart-Life Technologies. An SpeI 
restriction site was added at the 3’ of the tag-coding sequence to simplify the 
insertion of tag variants. The SH-Quant insert was introduced in the PvuI and PvuII 
restriction sites at the 5’ Gateway site of the pF3A-GST vector by double digestion 
with the two restriction enzymes and subsequently ligated to obtain the SH-pF3A-
GST destination vector.  
Flexi-Quant quantification strategy: The same cloning strategy as explained 
above was applied; here the SH-Quant peptide-coding sequence was replaced by a 
Flexi-Quant (TENLYFQGDISR)-coding sequence directly linked to a Strep-tag 
sequence (WSHPQFEK) at its 3’ to ultimately obtain a Flex-pF3A-GST destination 
vector. 
 
Reference peptide tag variants design for multiplexing 
The additional tags 2 to 5 described in Fig. 4 were designed by a first permutation of 
Ile residue 4 from the original SH-Quant tag sequence with amino acids of different 
hydrophobicity and size (G, A, V, F) to introduce molecular weight and/or retention 
time differences while not altering the fragmentation pattern. Additional tags 6 to 10 
were generated by a second permutation conservative of the charge by replacing 
Asp residue 3 by Glu in the 5 sequences generated as above. Hydrophilic residues 
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Thr 5 and Tyr 8 which produce intense y” fragment ions were kept constant to 
maintain solubility and sensitivity. The in vitro expression vector SH-pF3A-GST was 
modified via site-directed mutagenesis (QuikChange Lightning, Stratagene) 
according to the manufacturer’s protocol to generate the SH-quant peptide variant-
incorporating vectors (SHi-pF3A-GST). The I4G, I4A, I4V, I4F, D3E, D3E- I4G, D3E-
I4A, D3E-I4V, and D3E-I4F substitutions were introduced into SH-pF3A-GST using 
the forward and reverse primers presented in Supplementary Table 4, and 
sequence-verified. Proteotypicity of the newly designed tags was confirmed with 
Blast-P against the mouse protein database (http://blast.ncbi.nlm.nih.gov). 
 
In vitro-expressed TF identification 
In vitro-expressed proteins were in-gel digested using trypsin as follows: the samples 
were reduced in 10 mM dithioerythritol (DTE) and alkylated in 55 mM iodoacetamide 
(IAA) before being dried. The samples were then incubated with 12.5 ug/ml of trypsin 
(in 50 mM ammonium bicarbonate, pH 7.5) overnight at 37°C. The resulting tryptic 
peptides were extracted from the gel slices, dried, and resuspended in 2% 
acetonitrile (ACN): 0.1% formic acid (FA) for LC-MS/MS analysis. A mass 
spectrometer (LTQ Orbitrap XL (Thermo Fisher Scientific) equipped with an 
ultraperformance LC (UPLC) system (nanoACQUITY; Waters) was used. Peptides 
were trapped in a custom-made precolumn (Magic C18 AQ stationary phase, 5 μm 
diameter, 200Å pore, 0.1 × 20 mm, Michrom Bioresource) and separated in a 
custom-made main column (Magic C18 AQ, 3 μm diameter, 100Å pore, 0.75 × 150 
mm), using a run of 53 minutes and a gradient of H2O:ACN:FA 98%:2%:0.1% 
(solvent A) and ACN:H2O:FA 98%:1.9%:0.1% (solvent B). The gradient of the run 
was set at a flow rate of 250 nl/min as follows: 100% A for 3 min, 30% B within 
36 min, 47% B within 14 min, 90% B within 5 min and held for 5 min and 100% A for 
17 min. The MS/MS was operated in an information-dependent mode, in which each 
full MS analysis was followed by 10 MS/MS acquisitions during which the most 
abundant peptides were selected for collision-induced dissociation (CID) to generate 
tandem mass spectra. The normalized collision energies were set to 35% for CID. 
Data search was performed using Mascot software (v. 2.3; Matrix Science) and 
Proteome Discoverer (v.1.3; Thermo Fisher Scientific). The sequences were 
searched against a concatenated database consisting of a Triticum aestivum (wheat) 
database created from Uniprot database version 12.02 (4,684 sequences), the 
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sequences of the TF constructs expressed complemented with a set of common 
contaminant proteins sequences. Finally, the results were imported into Scaffold (v. 
3.3; Proteome Software) for validation of protein identification, normalization, and 
comparison of spectral counts. Peptide identifications were accepted if they could be 
established at a probability of >95% as determined by the PeptideProphet 
algorithm38. Protein identifications were accepted if they were assigned at least two 
unique validated peptides, and could be established with at least 99% probability as 
determined by the ProteinProphet algorithm39.  
 
Proteotypic peptide selection 
We initially turned to fragmentation spectra databases such as the NIST 
(http://www.nist.gov/nvl/) and PeptideAtlas40 to select the ideal pool of peptide 
candidates for the design of our SRM-based assay, aiming to monitor nuclear PPARγ 
and RXRα abundance during terminal adipogenesis. However, only a limited amount 
of information regarding TF-specific peptides could be retrieved. We therefore had to 
devise a strategy that did not rely on the use of publicly available information to 
discover proteotypic peptides of TFs. To alleviate concerns regarding the detectability 
of TFs, we implemented three different bi-dimensional peptide fractionation pipelines 
on 3T3-L1 total nuclear protein extracts at day four of differentiation (a time point at 
which the adipogenic master regulators PPARγ and RXRα are known to be highly 
expressed31, 41) with the precise aim of discovering TF-specific peptide candidates 
that could be utilized in downstream quantitative analyses. However, only two 
peptides for each TF were retrieved in spite of the higher resolving power provided by 
the extensive fractionation and the consecutive higher sensitivity expected in mass 
spectrometry (Supplementary Fig. 1). Thus, despite recent increases in overall 
sensitivity42, MS-based shotgun data-dependent methodologies are still lacking the 
combination of acquisition speed and sensitivity necessary to directly analyze low 
abundant proteins such as TFs within complex matrices derived from mammalian 
cells. The results of these preliminary experiments may also in part explain the 
scarcity of TF-specific peptides that we initially observed in databases. In response, 
we and others14 are currently undertaking significant efforts to address this TF data 
paucity, but it is clear that current TF-specific peptide repositories are still far from 
complete. An alternative strategy based on the combined use of proteotypic peptide 
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prediction tools43 and crude peptides synthesis44 did also not improve the quality of 
our acquired data. In fact, a great majority of the 51 crude synthetic peptides selected 
were either hardly or not consistently detectable over the time course of the 
experiment (data not shown). We attribute this behavior to peptide solubility, stability, 
and ionisability issues and decided therefore not to continue with this strategy. 
However, we followed the steps indicated below to select the representative 
proteotypic peptides. 
Peptide proteotypicity: candidate proteotypic peptides were selected using 
Pinpoint (v.1.1; Thermo Fischer Scientific) and their fragmentation spectra visually 
checked in Skyline45 using the spectral library inspection function. The following rules 
were applied in Pinpoint and Skyline to the tryptic peptides detected to ensure that 
only high quality peptides were retained for the analysis. 
 Peptide uniqueness: as a general rule, the TF-specific peptides selected here 
were uniquely representative of the TF of interest. In some instances however, 
empirically observed best-flying candidates were shared among two or more TF 
isoforms or TF subfamily members and were included in the assay. Discarding such 
candidates for less-than-optimal ones could compromise detectability. Therefore, the 
precision of absolute measurements accomplished utilizing such non-unique TF-
specific peptides may be affected to a certain extent by TF isoform(s) or subfamily 
counterpart(s). The following non-unique peptides were utilized in the multiplexed 
assay: ARID3a: peptide GLNLPTSITSAAFTLR is shared with ARID3b; NFIB: peptide 
EDFVLTVTGK is shared with NFIA, and GIPLESTDGER is shared with NFIA and 
NFIC; PIAS3: peptide VSELQVLLGFARG is shared with PIAS2; RXRα: peptide 
VLTELVSK is shared with RXRβ and ILEAELAVEPK is shared with RXRα; SMAD2: 
peptide VETPVLPPVLVPR is shared with SMAD3. 
Peptide detectability: only peptides spanning 7-25 amino-acids and falling 
within a mass range of 700 to 3,000 Da were used. N– or C–terminal peptides which 
could be degraded or modified in the protein of interest were excluded. The 
sequences immediately flanking the N– and C–terminal peptides of the target 
sequence were also excluded from the evaluation (the sequence linking the SH-
Quant tag to the N–terminus and the sequence linking the C–terminal peptide and 
the GST-tag sequence). 
Peptide digestability: as the whole methodology is peptide-centric and thus 
dependent on the completeness and specificity of the digestion step46, special care 
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was taken to ensure that only end-product peptides would be selected for the assay. 
This was especially true for the SH-Quant tag construction which contains a [KK] 
dibasic sequence at its C–terminal part which could lead to miscleavages. The SH-
Quant tag configuration was however retained as systematic attempts to detect 
miscleavage products originating from the [KK] dibasic sequence using either 
accurate mass inclusion mass spectrometry or targeted SRM detection were 
negative (i.e. only the SH-Quant tag end-product was detected). For all the other 
peptides, only fully tryptic peptides with no miscleavage other than [KP] and [RP] 
were considered. N– or C– terminal dibasic residues ([KK], [KR], [RK], [RR]) as well 
as surrounding acidic residues (E, D) in position P’1 and P’2 potentially leading to 
miscleavages were excluded. 
Peptide stability: peptide sequences containing oxidation-sensitive residues, 
methionine only in this case, were excluded. These peptides which usually ionize well 
were however kept as secondary choices in case no usable sequences would remain 
after the selection47. Peptides containing potential imide forming residues, [NG], 
potential deamidating residue, [DP], or N–terminal glutamine (Q) were excluded as 
well. 
Peptide selection: A first manual ranking of the proteotypic peptides was 
performed using peptide intensities extracted from the MS1 stage with the intention of 
selecting the best “flyers”. This ranking was complemented by a manual evaluation of 
the tandem MS spectral quality aimed at not excluding low intensity MS1 peaks with 
intense selective fragment ions (TIC MS2 in Supplementary Table 2). Specifically, 
tandem MS spectra presenting high intensity singly charged y’’ ions above the m/z of 
the parent ion were included in the second screen performed on the triple quadrupole 
instrument (TSQ Vantage, Thermo Fisher Scientific). In a preliminary SRM run, all 
selected peptides were targeted. The final best-responding candidates were selected 
by performing a pilot SRM analysis targeting the heavy labeled versions of the 
peptides selected in the previous screen spiked in a nuclear extract digest prepared 
in the same way as for the real experiment. A minimum of two peptides per TF was 
finally selected for the multiplex assay. 
 
Nuclear extract sample preparation and spiking of in vitro-expressed heavy TF 
and SH-Quant reference tags 
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Samples containing in vitro-expressed heavy TF were run on separate gel lanes 
allowing for maximal protein recovery. Gel bands were excised and split in four 
fractions of equal size, one of which was promptly utilized and the remaining ones 
were stored for future needs. Typically, expression levels of 3x to 4x were sufficient 
for 4 different multiplex assays. All in vitro-expressed heavy TFs were initially 
assessed for heavy isotope incorporation levels during a targeted SRM run. If 
required, this initial step can be utilized for external heavy TF quantitation using the 
SH-Quant tag, hence providing estimates on (spike-in) loads for a multiplex assay. 
This external quantitation is also used for precise adjustment of the light and heavy 
SH-Quant tag ratio, which in turn is fundamental for accurate quantitation using the 
multiplex approach. The basis for choosing the right quantities that need to be spiked 
in the case of TFs was determined by the necessity of achieving a good signal for the 
heavy labeled SH-Quant tags in the nuclear matrix (multiplex). For nuclear extracts 
(NE), 400 µg (quantified using the BCA assay) of total NE protein (differentiation 
times: Day 0 to Day 6) were separated and fractionated by SDS-PAGE using 10% 
Tris-Glycine gels. Gel bands were excised around the migration height of the proteins 
of interest: 50-60 kDa for RXRα and PPARγ, 30-40 kDa and 45-70 kDa in the 
multiplexed analysis (encompassing therefore all 10 TFs). 
Gel fractions of NE and heavy TFs were subsequently pooled for reduction 
and alkylation followed trypsin digestion, as described above. The accurately 
quantified SH-Quant tags (JPT Peptide Technologies) were added to each tube 
(200 fmol per tag) immediately after re-suspension in the digestion buffer. Following 
trypsinization, peptides were extracted from gel fractions and accurately aliquoted 
into four equal volumes (technical replicates). Samples were then dried using a 
speed vacuum and stored at –20°C prior to analysis. 
 
Liquid chromatography-mass spectrometry (LC-MS) analysis 
Dried aliquots (theoretical concentration: 100 μg) were re-suspended in 20 μl LC-MS 
loading solvent (2% acetonitrile, 0.1% formic acid) yielding a final, theoretical 
concentration of nuclear extract of 5 μg/μl. Following re-suspension, samples were 
allowed to settle for 1h to increase overall peptide solubility prior to analysis. 
Typically, 5 μl of sample (theoretical total: 25 μg) was loaded and captured on a 
home-made capillary pre-column (C18; 3 μm-200Å; 2 cm × 250 μm) prior to 
analytical LC separation (nanoACQUITY UPLC, Waters). Samples were separated 
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using a 90-minute biphasic gradient starting from 100% A solvent (2% acetonitrile, 
0.1% formic acid) to 90% B solvent (100% acetonitrile, 0.1% formic acid) on a Nikkyo 
(Nikkyo Technologies) nano-column (C18; 3 μm-100 Å; 15 cm length and 100 μm 
inner diameter, at a flow of 1 μl/min). The gradient was followed by a wash for 8 min 
at 90% solvent B and column re-equilibration of 12 min at 100% solvent A.   
 
Selected reaction monitoring (SRM) of TFs 
All samples were analyzed on a TSQ-Vantage triple-quadrupole mass spectrometer 
(Thermo Fisher Scientific). A 0.7 FWHM resolution window for both Q1 and Q3 was 
set for parent- and product-ion isolation. Fragmentation of parent-ions was performed 
in Q2 at 1.5 mTorr, using collision energies calculated with the Pinpoint software 
(v1.1). Parent-ion selection was set for fully digested peptides on the doubly charged 
ion for both SH-Quant tags and target proteins. Generally, singly charged peptide 
fragment ions ranging from y’’3 to y’’n-1 were preferably monitored, unless otherwise 
stated. A complete list of all monitored transitions is provided in Supplementary 
Data 2. A parent-ion retention time target window of 2 min to quantify RXRα or 
PPARγ and 5 min for the multiplexed quantification of ten TFs was set for Q1 during a 
scheduled SRM run. A total of respectively 88 and 76 transitions were monitored for 
RXRα and PPARγ in the single protein quantification strategy, whereas a total of 492 
transitions were typically monitored during a multiplex run. A cycle time of 0.5 s and 2 
s was used for single and multiplexed SRM runs respectively. A minimum dwell time 
of 10 ms or more was set for both single and multiplexed SRM assays. Samples 
were analyzed as three biological and three technical replicates (n=3) in RXRα and 
PPARγ single protein quantification assays. One biological replicate was analyzed in 
6 technical replicates as a proof-of-concept of the multiplex SRM assay. 
 
Evaluation of heavy TF isotope incorporation and miscleavage during SRM  
All in vitro-expressed heavy TFs were assessed for light isotope (K & R) 
misincorporation prior to SRM quantification. The amounts of isotope 
misincorporation (usually ≤ 5%) were corrected in the final calculations of absolute 
endogenous concentrations. In addition, all SH-Quant tags were monitored for trypsin 
miscleavage during a dedicated LC-MS run targeting the SH-Quant tag and its 
potential miscleavage products to assess the extent of digestion completeness. 
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Data analysis and absolute quantification of TFs 
Calculation of absolute levels of TFs was performed using a two-step procedure as 
outlined in Fig. 1b. All data analyses were carried out using Pinpoint software (v.1.1). 
Peptide identification and peak area integration of all SH-Quant tags and targeted 
peptides as well as their transitions were manually verified in Pinpoint. Ten individual 
standard curves were established for all SH-Quant tags using a concentration range 
of six values recorded in three technical replicates (Supplementary Fig. 14). The 
performance-based definitions of lower limits of quantification (LLOQ) were applied 
as defined by the FDA (Guidance for Industry: Bioanalytical Method Validation: 
http://www.fda.gov/cder/guidance/index.htm). Briefly, the threshold for the limit of 
detection (LOD) was set at 20% of the CV, whereas the LLOQ was set at 15% of the 
CV using three technical replicates for single- and six technical replicates for 
multiplex quantification approaches. An example of the LLOQ found for an SH-Tag is 
provided in Supplementary Fig. 15. An analysis of variance (ANOVA) coupled with a 
Neuwman-Keuls post-hoc test was applied for calculating the differences in 
endogenous levels of TFs between different differentiation time points, where the 
level of P<0.05 was considered as statistically significant. The calculation steps to 
derive absolute copy numbers per cell (nucleus) are presented in Supplementary 
Data 1.  
 
SRM assay validation using accurately quantified proteins 
Recombinant human α-synuclein (SYN, 15N heavy isotope, MW: 14,625 Da) and 
histidyl-tRNA synthetase (HARS, MW: 59,849 Da, ProspecBio, Israel) were 
accurately quantified by UV spectrophotometry using the protein’s molar extinction 
coefficient at 280nm and by amino acid analysis (AAA). The AAA was performed 
twice on two dilutions of the original protein solution at the Functional Genomics 
Center, Zurich (FGCZ) and gave a precision of ± 5%. Protein amounts corresponding 
to 5,000 (SYN = 3.64 ng, HARS = 14.3 ng) and 50,000 (SYN = 36.4 ng, HARS = 
143 ng) copies were spiked into nuclear extract (D0, 400 µg) and analyzed by SDS-
PAGE. SYN and HARS proteins were cut at their corresponding gel migration height 
as determined by reference proteins. In parallel, we retrieved the respective human 
ORFs (HARS, Thermo Fisher; SYN, in-house) and cloned them into our expression 
vector to enable the production of the respective heavy isotope-labeled proteins and 
thus to allow for a similar experimental workflow as the one used to quantify RXRα 
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and PPARγ. Gel bands were pooled and digested with the heavy SH-tagged protein 
and the accurately quantified SH-tags as outlined in the multiplex approach. SRM 
quantitation of spiked human (quantified by AAA) SYN and HARS peptides was 
achieved in a single SRM run using an 80 min LC gradient. A total of ten peptides 
were selected for HARS protein of which seven peptides share sequence homology 
with the mouse HARS protein, two peptides are proteotypic for human- and one 
peptide for mouse (endogenous) HARS. For SYN, two proteotypic peptides were 
monitored. Despite the high sequence homology between human and mouse SYN, 
endogenous levels of SYN could be accounted for by monitoring the ratio between 
the light (mouse endogenous) and the heavy 15N labeled peptides against the in 
vitro-expressed heavy SYN protein labeled at the terminal lysine. Samples were 
analyzed in three technical replicates.  
 
Motif Analysis 
Regions enriched with H3K27Ac as determined by Mikkelsen et al.,29 were scanned 
with FIMO48 allowing for a P value of 10–3. Each match in those regions was then 
scored for log-likelihood given by the position weight matrix of the PPARγ motif from 
the JASPAR CORE database49, assuming uniform background. 
 
PPARγ ChIP-seq data reanalysis 
ChIP-seq data from Nielsen et al. (26) was processed as in Raghav et al.31. 
 
Quantitative model of genome-wide TF DNA binding 
The estimation of the PPARγ DNA binding profile is based on equilibrium 
thermodynamics and is described in detail in the Supplementary Note.  
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Supplementary Figures 
Supplementary Figure 1. 
 
 
Supplementary Figure 1.  Diagram representing the 3 shotgun MS pipelines tested 
utilizing 3T3-L1 total nuclear protein extract at Day 4 of differentiation.  
Each pipeline employs a different peptide separation technique in the first dimension: SAX 
(strong anion exchange, 6 fractions), SCX (strong cation exchange, 20 fractions), and 
separation of peptides by their isoelectric point using an “Off-gel”  electrophoretic  system  (24  
fractions). The peptides were subsequently submitted to LC-MSMS for identification. The two 
adipogenic master regulators PPAR and RXR were specifically targeted. A maximum of 
only two peptides per TF were ultimately observed. 
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Supplementary Figure 2. 
 
 
 
Supplementary Figure 2. 10 in vitro-expressed GST-tagged TFs.   
The 10 in vitro-expressed TFs were run on a denaturing SDS-PAGE gel stained with silver 
nitrate. The molecular weights of the TF constructs (molecular weight of the TF + molecular 
weight of the GST-tag (26 kDa)) are presented in parentheses and their respective bands are 
indicated by an arrow. Peptide detection and protein identification for each TF construct was 
performed by in-gel digestion and LC-MS analysis. 
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Supplementary Figure 3. 
 
 
 
 
 
Supplementary Figure 3. Comparison of the performance of the FLEXIQuant and SH-
Quant peptide tags in SRM.  
(a) FLEXIQuant tag: Subpanel 1 shows the calculated standard curve regression line for the 
FLEXIQuant peptide (R2=0.878). Subpanel 2 shows peak profiles of different spikes of the 
FLEXIQuant peptide (1-6 fmol) in three technical replicates.  
(b) SH-Quant tag: Subpanel 1 shows the calculated standard curve regression line for the 
SH-Quant peptide (R2=0.969). Subpanel 2 shows peak profiles of different spikes of the SH-
Quant peptide (1-6 fmol) in three technical replicates. 
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Supplementary Figure 4. 
 
 
 
 
PPARγ peptide: LNHPESSQLFAK  
RXRα peptide: GLSNPAEALR
a b
c d
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3 4 5
 6 
Supplementary Figure 4. Evaluation of heavy PPAR “LNHPESSQLFAK”   and   RXR “GLSNPAEALR”   peptides in 3T3-L1 nuclear 
extract. 
Pinpoint screen prints, showing an example of the evaluation of heavy PPAR (a) (LNHPESSQLFAK) and RXR (c) (GLSNPAEALR) peptides, 
monitored at Day 0 through Day 6. The Pinpoint window provides a summary of the evaluation of the peptide of interest. Subpanel 1 shows an 
overview of all peptides monitored. Subpanel 2 shows the coefficients of variation per peptide at the different time points. Subpanel 3 shows the 
total normalized signal of all technical replicates (n=3). Subpanel 4 shows the peak profiles of all technical replicates. Subpanel 5 shows the 
chromatogram and calculated peak area of peptide transitions. Panel legend and numbering applies to panel (c) as well. Panels b and d show 
the calculated values of the PPAR and RXR heavy peptides spiked into nuclear extracts at Day 0 through Day 6. 
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Supplementary Figure 5. 
 
RXRα peptide: ILEAELAVEPK 
RXRα peptide: NSAHSAGVGAIF 
a b
c d
1 2
3 4 5
 8 
 
RXRα peptide: VLTELVSK 
RXRα peptide: AIVLFNPDSK 
e f
g h
 9 
 
 
 
 
Supplementary Figure 5. SRM monitoring of the five RXR peptides in 3T3-L1 nuclear extract. 
(a,c,e,g,i) Screen prints of all five RXR peptides monitored by SRM. The Pinpoint window provides a summary of the evaluation of the peptide 
of interest. Please see Supplementary Fig. 3 for a description of the subpanels. (b,d,f,h,j) Calculated amounts of endogenous levels found in 
nuclear extracts.  
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Supplementary Figure 6. 
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Supplementary Figure 6. SRM monitoring of the four PPAR peptides in 3T3-L1 nuclear extract. 
(a,c,e,g) Screen prints of all four PPAR peptides monitored by SRM. The Pinpoint window provides a summary of the evaluation of the peptide 
of interest. Please see Supplementary Fig. 3 for a description of the subpanels. (b,d,f,h) Calculated amounts of endogenous levels found in 
nuclear extracts. 
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Supplementary Figure 7. 
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Supplementary Figure 7. Calculated coefficient of variation of all RXR and PPAR peptides monitored by SRM.  
(a-b) Summary of all RXR and PPAR peptides monitored by SRM. Values are the mean ± SD of one biological sample analyzed in three 
technical replicates. The Pinpoint window provides a summary of the results as well as the calculated CV of RXR (c) and PPAR (d) peptides 
respectively. Please see Supplementary Fig. 3 for a description of the subpanels. Tables (e-f) summarize the calculated CV values for all RXR 
(n=5) and PPAR (n=4) peptides monitored by SRM. 
RXRα Parent Mass CV of peptides analyzed at day 0 to day 6
sequence m/z [M+2H]2+ day 0 day 0 + 2h day 1 day 2 day 4 day 6
ILEAELAVEPK 606.34 5% 3% 4% 4% 1% 3%
NSAHSAGVGAIFDR 701.34 6% 3% 5% 10% 16% 5%
VLTELVSK 444.77 3% <1% 1% 3% 1% 2%
AIVLFNPDSK 552.3 1% 1% 2% 3% 2% 1%
GLSNPAEALR 628.33 5% 3% 4% 3% 3% 2%
PPARγ Parent Mass CV of peptides analyzed at day 0 to day 6
sequence m/z [M+2H]2+ day 0 day 0 + 2h day 1 day 2 day 4 day 6
VEPASPPYYSEK 683.83 20% 14% 6% 2% 1% 5%
HLYDSYIK 519.76 27% 19% 17% 4% 1% 3%
SVEAVQEITEYAK 733.87 11% 1% 1% 1% 2% 1%
LNHPESSQLAK 685.85 11% 11% <1% 2% 2% 4%
e
f
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Supplementary Figure 8. 
 
 
Supplementary Figure 8. Immunoblotting analysis of PPAR and RXR expression 
levels found in 3T3-L1 nuclear extracts.  
(a) Validation of nuclear levels of PPAR (left panel: isoform II on top at 57.6 kDa, isoform I 
on the bottom at 54.5 kDa) and RXR (right panel: 51,2 kDa) expression by Western blotting 
using TF-specific primary antibodies in 3T3-L1 cells during six time points of terminal 
differentiation. PARP-1 was used as a nuclear loading control.  
(b) Densitometric analysis was performed for both PPAR (left) and RXR (right). Values 
were normalized against PARP-1 and Day 0 was taken as reference. Values of the 
subsequent days are represented in terms of fold changes. 
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Supplementary Figure 9. 
 
 
 
 
 
 
Supplementary Figure 9. Copy number assessment of RXR in 3T3-L1 nuclear 
extracts by (semi-)quantitative Western blotting (WB). 
(a-b) 3T3-L1 nuclear extracts of two independent biological replicates (Sample 1 and 2) were 
harvested at different time points during adipocyte differentiation (D0 to D6) and were 
Western blotted using RXR-specific antibody. To generate a standard curve, different 
amounts of in vitro-expressed, accurately quantified (by SRM) recombinant RXR were 
Western blotted using the same antibody (lanes 1-7 contain 20-0.31ng of recombinant 
RXR), after which their respective band intensities were analyzed by spot densitometry. 
This revealed two regimes indicative of linearity up to 10 ng (blue line) after which saturation 
dampens the signal (red line). Samples from day one to four were therefore diluted 3-fold to 
operate in the linear regime after which the dilution factor was taken into account to calculate 
final numbers as shown in c). (c) Bar graph showing the average RXR copy number at 
each differentiation time point based on Western blotting compared to that obtained by SRM. 
The number on top of the bar represents the fold change (FC) difference between the two 
assays. (d) Correlation between the copy number per cell calculated by SRM and Western 
blotting.  
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Supplementary Figure 10 
 
 
 
 
 
Supplementary Figure 10. SRM assay validation using two accurately quantified 
proteins. 
Recombinant human histidyl-tRNA synthetas (HARS) and human -synuclein (SYN) were 
accurately quantified by UV absorbance and amino acid analysis (Supplementary Methods). 
Proteins were mixed with nuclear extract (D0), separated by SDS-PAGE and quantified using 
the SH-tag multiplex approach.  
(a) LC-SRM spectrum of all HARS and SYN peptide fragments monitored by SRM. 
Proteotypic peptides for each protein are labeled as HARS and SYN respectively. Inset; total 
ion chromatogram (TIC) of light (spiked) and heavy labeled SH-tags for HARS and SYN, 
showing a clear distinction of both reference tags.  
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(b) The efficiency of SH-tag digestion and degree of recovery was assessed by monitoring 
the two SH-tags in a separate run. Recovery of both SH-tags was confirmed by identical 
signal intensities for parent- and fragment transition ions.  
(c) Measured variation (mean ± SD, n=3) found with HARS peptides (peptides are 
corresponding to 50,000 copies per cell of HARS). A total of nine peptides were monitored 
for HARS protein of which two peptides are proteotypic (highlighted in grey).  
(d) Measured variation of two proteotypic SYN peptides (mean ± SD, n=3; peptides are 
corresponding to 50,000 copies per cell of SYN). Endogenous (nuclear extract) HARS and 
SYN protein was assessed by monitoring mouse proteotypic peptides during each run.  
(e) Percentage of the spiked-in 5,000 and 50,000 copies per cell of HARS which were 
recovered after in-gel digestion followed by SRM quantification.  
(f) Percentage of the spiked-in 5,000 and 50,000 copies per cell of SYN which were 
recovered after in-gel digestion followed by SRM quantification.   
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Supplementary Figure 11. 
 
 
 
a 
b 
Supplementary Figure 11. Data evaluation using Pinpoint software. 
The screenshots show an example of the data evaluation using Pinpoint software as well as the 
coefficient of variation (CV) found with a proteotypic peptide of HARS (a) and SYN (b) 
respectively. A CV of 5% and 2% was measured for a proteotypic peptide of HARS and SYN 
respectively.  
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Supplementary Figure 12. 
 
 
 
 
 
 
Supplementary Figure 12. Assessment of the impact of gel extraction on protein 
quantification.  
In vitro-expressed, recombinant RXR was quantified using SRM after which different 
amounts were resolved on an SDS-PAGE gel and Western blotted using an RXR-specific 
antibody. A parallel series of corresponding bands were subsequently isolated and in-gel 
digested, after which the respective digests were subjected to SRM. The bar graph 
underneath shows the recovery percentage for each amount. These results indicate that for 
small  amounts  of  TF  (≤  2.5  ng),  protein  loss  after  gel  extraction,  digestion  etc.  may  amount  to  
~30%, whereas for larger amounts, the loss appears minimal (<~8%) as proteins likely 
function as carriers for themselves, consistent with the data derived from our HARS and SYN 
analyses. 
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Supplementary Figure 13. 
 
 
 
 
Supplementary Figure 13. PPAR and RXR protein copy number versus the number 
of detected binding sites. 
(a) Graph showing the PPAR protein copy number profile during terminal adipogenesis as 
detected by SRMs in relation to its binding site profile. A sharp increase in detected binding 
sites can be observed after Day 4, despite a saturation in PPAR protein copy numbers. 
(b) Graph showing the RXR protein copy number profile during terminal adipogenesis as 
detected by SRMs in relation to its binding site profile. An increase in detected binding sites 
can be observed after Day 4, despite a decrease in RXRprotein copy numbers. 
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Supplementary Figure 14. 
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Supplementary Figure 14. Establishment of standard curves for all ten SH-Quant tags 
used for multiplex SRM analysis. 
(a) All ten SH-Quant tags were spiked into nuclear extracts and analyzed in triplicates. 
Standard curves were established covering an on-column tag concentration range from 2.5 
fmol to 15.0 fmol in a complex matrix. Top panels: linear regression analysis (R2 = 0.960 – 
0.997) for all ten SH-Quant tags. Bottom panel: graphical representation of the variation 
found within all technical replicates (2.5 - 15 fmol) as well as the calculated value of an 
unknown treated sample (positive control) spiked into nuclear extract at 1.25 fmol.  
(b) Top panel: example of the calculated peak areas of two isobaric tags (tags 1 and 9), with 
slightly modified sequences, analyzed in three technical replicates at a concentration range 
of 1.25 – 15 fmol. Bottom panel: the table provides a summary of the calculated CV for all ten 
SH-Quant tags spiked at different concentrations (1.25 – 15 fmoles) into nuclear extracts. All 
samples were analyzed in triplicates.  
b
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Supplementary Figure 15. 
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Supplementary Figure 15. Standard curves obtained with the ten SH-Quant tags in 3T3-L1 nuclear extract. 
(a,c,e,g,i,k,m,o,q,s) Standard curves of all ten SH-Quant tags. The Pinpoint window provides a summary of the evaluation of the peptide-tags 
of interest. Subpanels 1 and 2 show an overview of the coefficients of variation per peptide-tag per time-point. Subpanel 3 shows the calculated 
standard curve regression line. Subpanel 4 shows the peak profiles of all technical replicates. Subpanel 5 shows the calculated peak area and 
chromatogram of peptide-tags transitions. Panel legend and numbering applies to all figures. (b,d,f,h,j,l,n,p,r,t) Calculated amounts of spiked 
samples. 
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Supplementary Figure 16. 
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Supplementary Figure 16. Determination of the lower limit of quantitation (LLOQ) of SH-Quant tags in multiplexed samples. 
(a) Example of the calculated peak area of a SH-Quant tag (AADITSLYK) spiked at concentrations of 15.0 fmol, 5.0 fmol, 2.50 fmol and 1.25 
fmol (unknown treated  sample).  Little  variation  (≤  0.15 min) in elution time was observed for all monitored concentrations.  
(b) The Pinpoint window provides a summary of the evaluation of the peptide-tags of interest. Subpanel 1 presents an overview of the all 
peptides monitored. Subpanel 2 shows the calculated peptide-tag amounts. Subpanel 3 shows the calculated standard curve regression line. 
Subpanel 4 shows peak profiles of different spikes of all technical replicates. Subpanel 5 shows the calculated peak area and chromatogram of 
the transitions of a lower-end peptide-tag. The calculated concentrations of all data points within the calibration curve were found to lie in the 
acceptable range of ± 15% variation. The red boxes highlight the peak area and concentrations found for   the   “unknown”  sample.  The   three  
technical replicates show little variation in concentrations (1.25 fmol, 1.11 fmol, 1.27 fmol, mean = 1.21 ± 0.09, variation ± 7.4%), which fulfills 
the acceptable range of variation as set by the FDA guidelines for the LLOQ (± 20%). A complete overview of all ten SH-Quant tags with the 
calculated concentrations can be found in Supplementary Figure 10. 
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Supplementary Figure 17. 
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Supplementary Figure 17. (a-j)  Screen prints of all peptides monitored by SRM for each of the 10 TFs at day two of differentiation.   
The Pinpoint window provides a summary of the evaluation of the peptides of interest of the 10 TFs. Subpanels 1 and 2 show the calculated 
amount of peptide found for each technical replicate. Subpanel 3 shows the total normalized signal of each individual technical replicate. 
Subpanel 4 shows peak profiles of each technical replicate. Subpanel 5 shows the calculated peak area and chromatogram of peptide 
transitions. Panel legend and numbering applies to all figures. 
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Supplementary Figure 18 
 
Supplementary Figure 18. Calculated peak areas of ten proteotypic peptides in their light and heavy versions. 
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Supplementary Tables 
Supplementary Table 1 
Supplementary Table 1: Comparison of available methods to our approach 
Method Pros (+) / Cons (-) How our method compares References 
SILAC PrEST  Over 18,000 clones available for human.  
 Spiked early in the pipeline. 
 In situ quantification possible for one protein. 
 AB available for independent validation of the 
results. 
 External quantification needed in a separate 
step with intermediate storage step for each 
single protein selected for multiplexing. 
 Requires in silico selection of proteotypic 
peptides to select the right clone(s). 
 
 Full-length protein expression. 
 GST clones easily available. 
 In situ quantification possible. 
 No intermediate storage of protein needed (source 
of error). 
 External accurate quantification still possible (to 
extend the number of proteins quantified at a time). 
 
Remark: Total number of full-length protein or PrEST 
spikable is limited if absolute sensitivity is required, so 
no advantage in multiplexing too much. 
Zeiler et al., 
Mol Cell Proteomics. 2012 March; 
11(3): O111.009613. 
PSAQ & 
FLEXIQuant & 
Absolute SILAC 
(Approaches based 
on the use of full-
length protein 
standard) 
 Mimics endogenous protein digestion behavior 
more accurately.  
 Spiked very early in the pipeline. 
 External quantification needed in a separate 
step with intermediate storage step for each 
single protein selected for multiplexing. 
 
 Multiplexing possible. 
 GST clones easily available. 
 Designed for multiplexed in situ quantification. 
 No intermediate storage of protein standard 
required (source of error). 
Singh et al., J Proteome Res. 2009 
May; 8(5):2201-10. 
Brun et al., J. Proteomics. 2009 Jul; 
72(5):740-9. 
Hanke et al., J. Proteome Res. 7, 
1118–1130 (2008). 
FLEXIQuant & EtEP 
(Approaches based 
on the use of a 
peptide-tag for 
quantification) 
 Simplification of the quantification procedure. 
 Only one peptide needs to be synthesized and 
accurately quantified. 
 In situ quantification limited to one protein 
(FlexiQuant) or loss of protein context (EtEP) 
 
 Multiplexing possible. 
 SH-Quant and the designed variants are 
proteotypic in mouse and human, stable over time 
in solution and sensitive.  
 
Remark: Peptidic tags are not equivalent. Therefore, any well-
flying peptide is not necessarily a good candidate. Careful 
validation needed to ensure that peptide is quantotypic 
(digestability, stability in solution, efficient fragmentation). 
Example: Flexiquant is not stable over time in solution and 
less sensitive than SH-Quant.  
 
Singh et al., J Proteome Res. 2009 
May; 8(5):2201-10. 
Holzmann et al., Anal. Chem. 81, 
10254–10261 (2009). 
 
QconCAT  Highest multiplexing capacity among methods 
available. 
 Systematic optimization needed. 
 Loss of protein context. 
 Difficult to express.  
 Only useful if more than 20 proteins have to 
be quantified at a time. 
 Multiplexing. 
 Useful in methods centered on a limited number of 
(low abundant) proteins. 
 Relative amounts of protein spiked easily adaptable 
to the endogenous levels of protein targets. 
 
Pratt et al., Nat Protocol. 2006; 
1(2):1029-43. 
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Supplementary Table 2
 
 
 
  
Supplementary Table 2: list of the 10 selected TFs
Gene 
symbol Name
DNA-binding 
domain IPI 
RXRa Retinoic acid receptor RXR-alpha zf-C4 P28700
Nfib Nuclear factor 1 B-type MH1 P97863
Pias3 E3 SUMO-protein ligase PIAS3 SAP O54714
Pias4 E3 SUMO-protein ligase PIAS4 SAP Q9JM05
Fosl2 Fos-related antigen 2 bZIP_1 P47930
Rarg Retinoic acid receptor gamma zf-C4 P18911
PPARg Peroxisome proliferator-activated receptor gamma zf-C4 P37238
Arid3a AT-rich interactive domain-containing protein 3A ARID Q62431
Nr2c1 Nuclear receptor subfamily 2 group C member 1 zf-C4 Q0VGP8
Smad2 Mothers against decapentaplegic homolog 2 MH1 Q62432
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Supplementary Table 3
 
Supplementary Table 3: calculations of PPARγ and RXRα copy-number per cell 
MS intensity # cells ug ugNE/cell copies/cell*
PPARγ Day 0 0.039 21825000 2025 9.28E-05 2179
2h 0.037 26475000 1876 7.09E-05 1579
Day 1 0.028 36150000 2048 5.67E-05 955
Day 2 0.069 39375000 2104 5.34E-05 2220
Day 4 0.153 61125000 4227 6.92E-05 6372
Day 6 0.072 56486250 3809 6.74E-05 2924
RXRα Day 0 0.33 21825000 2025 9.28E-05 18438
2h 0.252 26475000 1876 7.09E-05 10753
Day 1 0.518 36150000 2048 5.67E-05 17672
Day 2 1.399 39375000 2104 5.34E-05 45018
Day 4 0.883 61125000 4227 6.92E-05 36772
Day 6 0.357 56486250 3809 6.74E-05 14497
PPARγ Day 0 0.049 24975000 1380 5.53E-05 1630
2h 0.04 24450000 1420 5.81E-05 1399
Day 1 0.092 29287500 1532 5.23E-05 2898
Day 2 0.281 42000000 2036 4.85E-05 8203
Day 4 0.303 48000000 2819 5.87E-05 10716
Day 6 0.299 43950000 3174 7.22E-05 13003
RXRα Day 0 0.245 24975000 1380 5.53E-05 8152
2h 0.314 24450000 1420 5.81E-05 10982
Day 1 0.627 29287500 1532 5.23E-05 19751
Day 2 0.945 42000000 2036 4.85E-05 27587
Day 4 0.468 48000000 2819 5.87E-05 16552
Day 6 0.281 43950000 3174 7.22E-05 12221
PPARγ Day 0 0.108 24900750 1270 5.10E-05 3317
2h 0.074 29025000 1260 4.34E-05 1935
Day 1 0.182 45234000 1500 3.32E-05 3634
Day 2 0.342 53700000 2050 3.82E-05 7862
Day 4 0.308 56212500 2500 4.45E-05 8249
Day 6 0.235 57412500 2620 4.56E-05 6458
RXRα Day 0 0.191 24900750 1270 5.10E-05 5866
2h 0.321 29025000 1260 4.34E-05 8392
Day 1 0.459 45234000 1500 3.32E-05 9166
Day 2 1.099 53700000 2050 3.82E-05 25265
Day 4 0.646 56212500 2500 4.45E-05 17301
Day 6 0.445 57412500 2620 4.56E-05 12229
NE: nuclear extract
3rd biological replicate
2nd  biological replicate 
1st  biological replicate 
(1 TF per assay)
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Calculations of 10 TFs copy-number per cell (multiplex)
MS intensity # cells ug ugNE/cell copies/cell*
RXRα Day 0 0.174 22650000 1264 5.58E-05 5847
Day 2 0.551 20175000 1466 7.27E-05 24111
Day 4 0.307 37275000 2249 6.03E-05 11155
PPARγ Day 0 0.07 22650000 1264 5.58E-05 2352
Day 2 0.194 20175000 1466 7.27E-05 8489
Day 4 0.176 37275000 2249 6.03E-05 6395
Pias3 Day 0 0.023 22650000 1264 5.58E-05 773
Day 2 0.011 20175000 1466 7.27E-05 481
Day 4 0.007 37275000 2249 6.03E-05 254
Pias4 Day 0 0.172 22650000 1264 5.58E-05 5780
Day 2 0.174 20175000 1466 7.27E-05 7614
Day 4 0.136 37275000 2249 6.03E-05 4941
NFIB Day 0 5.659 22650000 1264 5.58E-05 190178
Day 2 6.984 20175000 1466 7.27E-05 305608
Day 4 4.703 37275000 2249 6.03E-05 170879
SMAD2 Day 0 0.431 22650000 1264 5.58E-05 14484
Day 2 0.341 20175000 1466 7.27E-05 14922
Day 4 0.32 37275000 2249 6.03E-05 11627
RAR Day 0 0.129 22650000 1264 5.58E-05 4335
Day 2 0.106 20175000 1466 7.27E-05 4638
Day 4 0.104 37275000 2249 6.03E-05 3779
NR2C1 Day 0 0.043 22650000 1264 5.58E-05 1445
Day 2 0.041 20175000 1466 7.27E-05 1794
Day 4 0.037 37275000 2249 6.03E-05 1344
FOSL2 Day 0 0.077 22650000 1264 5.58E-05 2588
Day 2 0.093 20175000 1466 7.27E-05 4070
Day 4 0.073 37275000 2249 6.03E-05 2652
ARID3a Day 0 0.015 22650000 1264 5.58E-05 504
Day 2 0.013 20175000 1466 7.27E-05 569
Day 4 0.013 37275000 2249 6.03E-05 472
4th  biological replicate
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Tag name (amino acid substitution) nucleotide sequence (5’ to 3’)
SH24-pF3A-GST (I4G) FW atcgatggaaaaagcggccgatggcacaagtttgtacaaaaaagc
RV gcttttttgtacaaacttgtgccatcggccgctttttccatcgat
SH25-pF3A-GST (I4A) FW atcgatggaaaaagcggccgatgccacaagtttgtacaaaaaagc
RV gcttttttgtacaaacttgtggcatcggccgctttttccatcgatt
SH26-pF3A-GST (I4V) FW cgatggaaaaagcggccgatgtcacaagtttgtacaaaa
RV ttttgtacaaacttgtgacatcggccgctttttccatcg
SH27-pF3A-GST (I4F) FW cgatggaaaaagcggccgatttcacaagtttgtacaaaa
RV ttttgtacaaacttgtgaaatcggccgctttttccatcg
SH28-pF3A-GST (D3E) FW cgatggaaaaagcggccgagatcacaagtttgtacaaaa
RV ttttgtacaaacttgtgatctcggccgctttttccatcg
SH29-pF3A-GST (D3E- I4G) FW gatcgatggaaaaagcggccgagggcacaagtttgtacaaaaaagctg
RV cagcttttttgtacaaacttgtgccctcggccgctttttccatcgatc
SH30-pF3A-GST (D3E-I4A) FW gatcgatggaaaaagcggccgaggccacaagtttgtacaaaaaagctg
RV cagcttttttgtacaaacttgtggcctcggccgctttttccatcgatc
SH31-pF3A-GST (D3E-I4V) FW cgatcgatggaaaaagcggccgaggtcacaagtttgtacaaaaaag
RV cttttttgtacaaacttgtgacctcggccgctttttccatcgatcg
SH32-pF3A-GST (D3E-I4F) FW cgatcgatggaaaaagcggccgagttcacaagtttgtacaaaaaag
RV cttttttgtacaaacttgtgaactcggccgctttttccatcgatcg
Supplementary Table 4: primers used to generate SH-quant variants
Supplementary Note
Simicevic et al.
1 Outline
The goal of the following model is to determine if the temporal progression of detected PPAR γ
binding sites during adipogenesis is consistent with the SRM-based measurement of PPAR γ copy
numbers. The first part of this note addresses the modeling of protein binding (cf. Section 2 and
Supplementary Fig. 19: Modeling protein binding) which aims at predicting the occupancy of the
di!erent specific sites pi , assuming that we know the number of transcription factor molecules N ,
the size of the accessible genome M and the affinity of the di!erent binding sites X i . The second
part of this note describes how to estimate the affinities X i of the accessible specific sites from
genome-wide ChIP-seq and accessibility data using the position weight matrix of the PPAR γ motif
(cf. Section 3 and Supplementary Fig. 19: Estimating binding sites affinity). This allows us to
reconstruct the affinity distribution of the di!erent specific sites in the accessible regions of the
genome. In the last part of this note, we estimate the occupancy threshold pt above which PPAR γ
binding sites are detected(cf. Section 4 and Supplementary Fig. 19: Prediction). We find that
this threshold is in the range of 1% which is comparable to the % input of standard ChIP-seq
experiments.
2 Statistical Modeling of protein binding
2.1 Statistical Mechanics Approach
The first question we want to address is how many protein molecules on average are bound to
specific sites in a given cell. The approach used to compute the occupancy of the di!erent specific
sites is based on statistical mechanics. The main idea consists in enumerating all the di!erent
configurations by which one can place N proteins on the accessible genome weighted by the
Boltzmann factor exp (− βE ) , which determines the likelihood of a configuration depending on its
energy E . Typically, this is achieved by means of the partition function which describes the statis-
tical properties of the system at thermodynamical equilibrium [ 1].
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Supplementary Figure 19. Flowchart of the modelling process.
For the sake of simplicity, we made the following assumptions regarding our system: 1) we
considered only one species of protein, 2) all the proteins are assumed to be on the DNA [2, 3]
(either at specific sites or non-specific sites), 3) we do not consider hindrance between possibly
(but very unlikely) overlapping sites, 4) we model k categories of specific sites of different affinity
and all of these sites are assumed to be stronger than non-specific sites. Consequently, the system
can be parametrized in the following way. N is the total number of proteins in the nucleus, M the
size of the accessible genome, mi the number of specific sites of category i, ni the number of
proteins bound to sites of category i and the energy Ei associated with each category of sites i.
Therefore, the partition function Z of the system can be written as:
Z(N) =
NX
n1,n2,...,nk=0
✓
M  m
N   n
◆
exp (  (N   n)E0)
(
kY
i=1
✓
mi
ni
◆
exp (  niEi)
)
with m =
Pk
i=1mi the total number of specific sites, n =
Pk
i=1 ni the number of proteins bound
to specific sites and E0 the energy of an non-specific site. We can compute the average number
of proteins n¯i which are bound to specific sites of category i, with the derivative of the log of the
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partition function with respect to the energy Ei:
n¯i =   1
 
@
@Ei
logZ(N)
It follows that the mean occupancy pi of a site i is given by:
pi =
n¯i
mi
In the following, it is convenient to rewrite the partition function in term of the affinities Xi =
exp (  (Ei   E0)) of the different sites where the reference energy is chosen as the energy of
the non-specific sites E0. Consequently, the affinity of a non-specific site is X0 = 1 and the parti-
tion function is now given by:
Z(N) =
NX
n1,n2,...,nk=0
✓
M  m
N   n
◆( kY
i=1
✓
mi
ni
◆
Xnii
)
(1)
It is possible to compute an approximate expression for the average number of occupied specific
sites n¯i and their occupancy pi in two different regimes: either the number of proteins is in excess
compared to number of specific sites, or the number of specific sites is much larger than the
number of proteins.
2.2 Regime 1: Excess of Proteins over Specific Sites
In this first regime, we assume that the number of proteins N is much larger than the total number
of specific sites m but that N is still small compared to the size of the accessible genome M ,
namely:
M   N   m =
kX
i=1
mi with mi   ni 8i 2 {1, 2, ..., k}
The average number of occupied sites and the mean occupancy of a site can be derived rigorously
from the partition function by approximating the binomial coefficients. Here, we present a more
intuitive approach leading to the same results. By setting mi = 1 and mj = 0 8j 6= i in the partition
function (1), we can compute the probability P (b|N,m = 1) that a specific site i is bound given that
we have only one specific site in the genome and N proteins. We find that:
P (b|N,m = 1) =
N
MXi
M N
M +
N
MXi
'
N
MXi
1 + NMXi
which is the famous Hill function where the occupation of the site depends on the concentration
of proteins N/M and the affinity of the site Xi. Since there are many proteins compared to the
number of specific sites, each site can be seen as independent from others, namely we neglect
the depletion of the protein pool due to binding at specific sites. Therefore, the average number of
specific sites which are occupied n¯i is given by P (b|N,m = 1) multiplied by the number of sitesmi:
n¯i = mi
N
MXi
1 + NMXi
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The mean occupancy pi = n¯i/mi of a site of category i is then identical to P (b|N,m = 1):
pi =
N
MXi
1 + NMXi
2.3 Regime 2: Excess of Specific Sites over Proteins
In the second regime, we assume that the number of specific sites mi and the number of non-
specific sites m0 = M   m are much larger than the number of proteins N . This can be stated
as:
M =
kX
i=0
mi with mi   N   ni 8i 2 {0, 1, ..., k}
From the partition function (1), one can compute the probability P (b|N = 1, {mi}) that one protein
is bound to a specific site given the set of specific sites {mi} and that the total number of proteins
is one, this probability is given by:
P (b|N = 1, {mi}) =
mi
M Xi
m0
M +
Pk
i=1
mi
M Xi
The probability that one protein is bound to a specific site now depends on the concentrations of
sitesmi/M and the affinitiesXi of the different sites. Since the number of sites is much larger than
the number of proteins, each protein can be considered as being independent from each other. The
average number of proteins n¯i which are bound to specific site i is then given by P (b|N = 1, {mi})
times the number of proteins N :
n¯i = N
mi
M Xi
m0
M +
Pk
i=1
mi
M Xi
Thus, the expression for the mean occupancy pi = n¯i/mi of a site of category i is similar that in
the first regime except that the denominator now depends on the concentrations of sites mi/M :
pi =
N
MXi
m0
M +
Pk
i=1
mi
M Xi
In the above expression, since X0 = 1, the denominator can be expressed in term of the average
affinity of the sites X¯ which depends on the distribution of affinities in the accessible genome
P (Xi) = mi/M , therefore we obtain:
pi =
N
MXiPk
i=0
mi
M Xi
=
N
MX¯
Xi
2.4 Typical Parameters
The size of the accessible mice genome is typically less than 10% of the full genome, consequently
M ⇠ 108 bp. Regarding the number of proteins, the measured number for PPAR  and RXR↵ were
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approximately in the range of N ⇠ 103 proteins. The number of binding sites which were detected
is approximately m ⇠ 103 sites [4], it is important to realize that those represent the stronger sites,
weaker sites are most likely not detected. Finally, the dissociation constant Kd is typically in the
order of µM for a non-specific site and nM for a strong site, consequently we can assume that a
strong site has an affinity roughly 103 times larger than a non-specific one [3].
Given those numbers, the first regime (Section 2.2) where the proteins are assumed to be in
excess is clearly not adequate, since the number of detected binding sites is in the range of the
number of proteins 103. Despite the fact that in our case the strongest sites might be fewer than the
number of proteins N , most of the sites will actually be in large excess compared to N , therefore
the second regime (Section 2.3) is appropriate to describe the occupancies of the different sites
in our ChIP-seq experiments. In fact, it also predicts very well the behavior of the strongest sites
(cf. Supplementary Fig. 20), because the strongest sites are not saturated due to the competition
with the very large number of less favorable sites. Consequently, we expect a linear relationship
between the occupancy and the affinity of the sites.
pi =
N
MX¯
Xi (2)
If the non-specific sites dominate, namely the affinities Xi decrease fast enough compared to the
increase in number of sites mi, then the mean affinity of the sites will be close to one X¯ ' 1. This
might not be true in practice, we will see later how to estimate the coefficient X¯ (Section 3.4).
3 Link between ChIP-seq signal and affinity
3.1 Simple ChIP-seq Model
In a ChIP-seq experiment, the signal, i.e. the average number of fragments Si for any sites of type
i, should reflect the mean occupancy of the sites pi. Of course, the occupancy is not the only
contribution to the signal, the efficiency and specificity of the antibody as well as the number of
cells play an important role, but those effects can be implicitly included in a simple model:
Si = Api +B
where as a first approximation the signal Si is proportional to the occupancy pi plus some back-
ground B [5]. Since in our case the occupancy goes as pi ' NMX¯Xi, we expect a correlation
between the affinity Xi and the mean signal Si:
Si =
AN
MX¯
Xi +B (3)
3.2 Link between Energy and PWM Log-likelihood
In practice, one does not necessarily know the binding energy of the sites of interest, but if we know
the position weight matrix (PWM), it is then possible to make the link between each sequence and
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its binding energy [5, 6]. In the PWM framework the binding energy of the site " =   E is assumed
to be the sum of independent contributions of each base "k(b). If the binding sites are characterized
by an average energy "¯, one can express the likelihood q(s) that a randomly chosen binding sites
of length L will have sequence s:
q(s) =
LY
k=1
exp ( "k(sk))P
b exp ( "k(b))
=
LY
k=1
fk(sk)
where the selection parameter   ensures that "¯ =
P
s "(s)q(s) and fk(b) is the frequency of obser-
vation of base b at position k. Therefore, the log-likelihood z(s) = log (q(s)) is related to energy by
the factor   plus a constant:
z = log (q) =  "+ cst
We can express the energy of the sites with respect to the consensus sequence which is assumed
to be the best sequence with the largest log-likelihood zmax = log (qmax):
  (Ei   Ec) = 1
 
(zi   zmax)
where Ec is the energy of the consensus. Finally the affinities Xi in term of the log-likelihood are
given by:
Xi = Xmax exp
✓
1
 
(zi   zmax)
◆
(4)
where Xmax = exp (  (Ec   E0)) is the affinity of the consensus sequence. In the following we
will assume that Xmax = 103 which is the typical magnitude for the strongest sites compared to
non-specific ones [3].
3.3 Estimating the Parameter  
Using our simple model for the ChIP-seq signal, we can now relate the log-likelihood score zi of
the different sites with the signal. Indeed, from equation (3) and (4), the signal is given by:
Si = A0 exp
✓
1
 
zi
◆
+B (5)
where A0 is a new proportionality constant. Therefore, it is possible to estimate the   parameter of
the PPAR  motif from the ChIP-seq signal. This enables us to make the link between the energy
scale and the log-likelihood score.
We focused on PPAR  at day 0, day 2 and day 6, we used the motif from the JASPAR CORE
database [7] and we screened the accessible genome with FIMO [8] from the MEME suite for all
the sequences which had a p-value < 10 3. Due to limited sequencing depth of available DHS
data, we used the H3K27ac regions from Tarjei et al. [9] as a proxy for the accessible genome. We
verified that these regions cover most of the reported PPAR  sites. The size of these regions were
similar between the three time points, M0 = 5.97 · 107 bp, M2 = 6.99 · 107 bp and M6 = 6.76 · 107
bp. For each of those three time points, we estimated the parameter   using the mean ChIP-seq
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signal for different category of sites, namely we separated the sequences in 6 bins of log-likelihood
covering the range obtained with FIMO (cf. Supplementary Fig. 21). We estimated the background
level for the three time points by taking a window of 200 bp shifted by 1000 bp from each peak, we
obtained B0 = 1.273, B2 = 1.146 and B6 = 2.004. Since there is not much ChIP signal at day 0
(very few PPAR  proteins before induction), we estimated the   parameter as the average of day
2 and 6, we obtained   ' 3.36.
3.4 Estimating X¯
In the second regime, where the specific sites are in excess compared to proteins, we showed in
Section 2.3 that the occupancy can be expressed as follows:
pi =
N
MXiPk
i=0
mi
M Xi
=
N
MX¯
Xi
where X¯ is actually the average affinity of the sites X¯ =
Pk
i=0XiP (Xi). We estimated X¯ using the
theoretical distribution of sites with respect to the log-likelihood ⇢(z) given by the PWM of PPAR :
X¯ =
Z zmax
zmin
X(z)⇢(z)dz (6)
where X(z) is given by equation (4) above the non-specific threshold z? = zmax     log (Xmax)
which corresponds to the limit where non-specific binding starts to dominate. Therefore, X(z) can
be expressed as:
X(z) =
(
Xmax exp
 
1
 (z   zmax)
 
z > z?
X0 = 1 z  z? (7)
We approximated the probability density distribution ⇢(z) as a normal distribution N (z; z¯, z). We
sampled the distribution from the PWM in order to estimate the mean z¯ =  32.69 and the standard
deviation  z = 5.33. Performing the integral (6), we obtained X¯ ' 1.93. A correction to the
normal distribution based on the saddle-point approximation [10] did not change much the result
(X¯ ' 1.97).
4 Predicting the number of binding sites
4.1 Occupancy Threshold
In order to predict the number of binding sites that should be detected in our ChIP-seq data, we
assume that there is a certain occupancy threshold pt above which we will start detecting the sites.
We can now express this threshold in term of the log-likelihood. Indeed, from equation (2) and (4)
the occupancy can be expressed as :
pt =
NXmax
MX¯
exp
✓
1
 
(zt   zmax)
◆
(8)
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Inverting this relation gives the log-likelihood threshold zt:
zt =   log
✓
MX¯pt
NXmax
◆
+ zmax (9)
Given this threshold zt and the density of sites with respect to the log-likelihood, we will be able
to predict the number of binding sites Nsites(zt), by counting how many sites in the accessible
genome (section 3.3) have a log-likelihood larger than zt.
4.2 Number of Binding Sites
We used the same approach than the previous section 3.3 to screen the accessible genome in
order to model the cumulative number of sites Nsites(z) with respect to the log-likelihood z. In
order to obtain a smooth representation, it is convenient to parametrize the tail of Nsites(z) as a
power-law:
Nsites(z) = C(z0   z)k (10)
where k is the power law exponent, C and z0 are constants. We estimated the parameters C, k
and z0 for PPAR  at day 0, day 2 and day 6 using non-linear least squares, this representation
gives excellent results (cf. Supplementary Fig. 22). Knowing the log-likelihood threshold zt above
which we should start to detect sites, we can predict the number of sites by evaluating (10) in zt:
Nsites(zt) = C(z0   zt)k with zt =   log
✓
MX¯pt
NXmax
◆
+ zmax (11)
We determined the log-likelihood threshold zt for the three different time points using equation (9)
and the measured proteins copy number N0 = 2376, N2 = 6095, N6 = 7462 which were average
over the three biological replicates. The occupancy threshold pt is a free parameter which was
assumed to be the same between each time points, it was chosen so that the squared error be-
tween the detected number of sites and the predicted one is minimized, we obtained pt ' 1.35%
(cf. Supplementary Fig. 23) which is comparable to % input values in a good ChIP experiment
[11]. We remind the reader that % input would correspond to occupancy in the case of an ideal
ChIP (100% efficient antibody).
4.3 Independent Validation
We tested our model with a different set of ChIP-seq data provided by Siersbaek et al. [12] al-
though they only performed ChIP-seq on PPAR  at day 2 and 6 after induction. Following a similar
approach than in section 3.3 and using the same DNA accessibility marks, we fitted the selection
parameter and obtained   ' 2.69. Using the measured copy number as in section 4.2 and as-
suming no detected PPAR  binding site at day 0, we then minimized the squared error between
the detected and predicted number of binding sites for the three time points, and we obtained an
occupancy threshold of pt ' 0.98% (cf. Supplementary Fig. 23) which is in the same range as the
value we obtained in the previous section (section 4.2). Despite the new selection parameter, the
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prediction for both data set are in good agreement. If we average both the selection parameter and
the number of detected binding sites from [4] and [12], the model is then in excellent agreement
with the average detected binding sites (cf. Supplementary Fig. 23).
4.4 Discussion
Our model makes a few assumptions that merit discussions. First, since we did not know the affin-
ity of the best sites in vivo, we assumed that the strongest sites, namely sites corresponding to the
consensus sequence, were 1000 fold stronger than non-specific sites (Xmax = 103), which is real-
istic [3]. In addition, we computed how the predicted occupancies pi depend on this number trough
the ratio Xi/X¯ (cf. Supplementary Fig. 24). We observe two regimes: one when Xmax > 103
where Xi/X¯ becomes insensitive to Xmax. Secondly when Xmax < 103 (which is unlikely biologi-
cally), the predicted occupancies would decrease, but this could be compensated by lowering the
occupancy threshold pt. Thus, our conclusions on the behavior of the number of sites vs proteins
number do not strongly depend on the presumed value of Xmax.
As a second assumption, we did not model explicitly the dimer between PPAR  and RXR↵,
which is justified since PPAR  is in limiting amounts. Moreover, we neglected the hindrance due
to other protein species which could distort the predicted occupancies. Indeed, many proteins are
interacting with DNA and thereby obstruct the accessible sites [13]. In particular, this might reduce
the size of the genomic regions that are effectively accessible for PPAR  and consequently the
occupancy of the sites might be higher. Nevertheless, the values derived for the occupancy (2) will
not be strongly affected since the product MX¯ would only be mildly changed if we assume that
additional proteins would essentially deplete non-specific or weak PPAR  binding sites. Indeed, if
we assume that one third of the transcription factors of the mouse (⇠ 850 TFs) are expressed at an
average level of 104 copies [14], we would obtain NTF ' 8.5 · 106 molecules in the nucleus which
is still small compared to the measured accessible genome sizeM ' 6.8 · 107.
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Supplementary Figure 20. Top: site occupancy p with respect to affinity X, computed with the
approximate expression (2) and exactly from the partition function (1), for a reduced system with
comparable concentration of proteins than PPAR  at day 6 (cf. Section 3.3). The theoretical
distribution of sites with respect to the affinity given by the PWM of PPAR  was discretized in
k = 20 categories, covering the range of affinities [X0 = 1, Xmax = 1000]. Bottom: comparison
between the approximate and exact occupancy for the same system. Even if the stronger sites are
in low amount compared to the number of proteins (m19 = 1, m18 = 2, ..., m14 = 80 < N = 100),
the approximation (2) still predicts very well their occupancy.
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Supplementary Figure 21. Left column: fitting of the selection parameter   from the mean ChIP-
seq signal at day 0, day 2 and day 6 in log-space. Right column: representation of expression (5)
in real space, using the estimated parameters on the left.
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Supplementary Figure 22. Left: cumulative number of sites found in H3K27ac regions with FIMO
[8] at day 0, day 2 and day 6. Right: cumulative number of sites approximated as a power law, this
representation gives excellent results R2 > 0.99.
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Supplementary Figure 23. Left: predicted number of PPAR  binding sites based on Nielsen et
al. ChIP-seq data [4]. Right: predicted number of PPAR  binding sites based on Siersbaek et
al. ChIP-seq data. [12] Bottom: predicted number of PPAR  binding sites compared to average
number of detected sites in both [4] and [12].
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Supplementary Figure 24. Effect of Xmax on the ratio Xmax/X¯ which appears in the occupancy
expression (8). If Xmax > 103, the ratio becomes insensitive to Xmax. On the other hand, if
Xmax < 103, the occupancy will decrease.
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Supplementary	  Data	  1:	  proteotypic	  peptide	  selection	  for	  the	  10	  TFs	  (multiplex)
PeptideAtlas	  query	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  on	  14Apr2012
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Supplementary	  Data	  1:	  proteotypic	  peptide	  selection	  for	  the	  10	  TFs	  (multiplex)
Protein	  Name/Accession.
Peptide	  Atlas	  accession	  number,	  beginning	  with	  PAp	  followed	  by	  9	  digits.
Preceding	  (towards	  the	  N	  terminus)	  amino	  acid
Amino	  acid	  sequence	  of	  detected	  pepide,	  including	  any	  mass	  modifications.
Following	  (towards	  the	  C	  terminus)	  amino	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Length	  of	  peptide
Score	  genereated	  based	  on	  STEPP,	  PSieve,	  ESPP,	  APEX	  and	  DPred	  scores
Predicted	  peptide	  score	  calculated	  by	  Peptide	  Sieve	  algorithm
Predicted	  peptide	  score	  calculated	  by	  ESPP	  algorithm
Predicted	  peptide	  score	  calculated	  by	  Detectability	  Predictor	  algorithm
Predicted	  peptide	  score	  calculated	  by	  APEX	  algorithm
Predicted	  peptide	  score	  calculated	  by	  STEPP	  algorithm
Number	  of	  SwissProt	  primary	  protein	  mapping
Number	  of	  SwissProt	  primary	  and	  alternatively-­‐spliced	  protein	  mapping
Number	  of	  SwissProt	  primary	  and	  alternatively-­‐spliced	  protein	  mapping,	  plus	  nsSNP	  mapping,wherein	  all	  Swiss-­‐Prot-­‐annotated	  nsSNPs	  have	  been	  expanded	  out	  to	  sequence	  with	  context	  so	  that	  any	  nsSNP-­‐containing	  peptides	  are	  properly	  mapped.
Number	  of	  Ensembl	  protein	  mapping
Number	  of	  Ensembl	  gene	  mapping
Number	  of	  IPI	  protein	  mapping
Number	  of	  Human	  protein	  mapping,	  including	  SwissProt,	  IPI	  and	  Ensembl	  Proteins
Number	  of	  Mouse	  protein	  mapping,	  including	  SwissProt,	  IPI	  and	  Ensembl	  Proteins
Number	  of	  Yeast	  protein	  mapping,	  including	  SwissProt,	  SGD	  and	  Ensembl	  Proteins
MS1	  intensities	  as	  determined	  using	  MaxQuant	  on	  OrbitrapXL	  data.	  Bar	  length	  proportional	  to	  intensity.	  The	  longer	  the	  higher.
MS1	  intensity	  ranking.	  Bar	  length	  inversly	  proportional	  to	  ranking.	  The	  shorter	  the	  better.
Ranking	  of	  Total	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  Current	  in	  tandemMS	  spectrum	  as	  extracted	  from	  Scaffold	  for	  doubly	  charged	  ions.	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  length	  inversly	  proportional	  to	  ranking.	  The	  shorter	  the	  better.
Ranking	  of	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  in	  tandemMS	  spectrum	  as	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  from	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  triply	  charged	  ions.	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  length	  inversly	  proportional	  to	  ranking.	  The	  shorter	  the	  better.
Number	  of	  protein	  mapped	  by	  peptide	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  1	  and	  3	  were	  highlighted	  in	  green	  (Peptide	  sequence	  specificity)
Number	  of	  protein	  mapped	  by	  peptide	  sequence	  above	  3	  were	  not	  highlighted	  (Peptide	  sequence	  specificity)
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1 P47930	   	  	   R	   GTGSAVGPVVVK	   Q	   12 0.92 0.83 0.66 0.78 0.1 0.61 1 1 1 1 1 2 0 4 3430300 1 1
5 P47930	   PAp01458922	  K	   LQAETEELEEEK	   S	   12 0.78 0.75 0.37 0.6 0.02 0.57 1 1 1 1 1 2 6 4 2874200 2 2
11 P47930	   	  	   R	   DEQLSPEEEEK	   R	   11 0.06 0.07 0.21 0.42 0 0.47 1 1 1 1 1 2 9 4 1007800 3
9 P47930	   	  	   R	   SPPTSGLQSLR	   G	   11 0.18 0.18 0.63 0.69 0.02 0.33 1 1 1 1 1 2 0 4 918780 4
13 P47930	   	  	   K	   EIAELQK	   E	   7 0.04 0.02 0.27 0.09 0 0.39 3 4 4 8 3 6 30 18 711070 5
2 P47930	   PAp01750725	  R	   SSSSGDQSSDSLNSPTLLAL	   -­‐	   20 0.92 0.91 0.48 0.82 0.04 0.81 1 1 1 1 1 2 7 4
3 P47930	   PAp00154775	  -­‐	   MYQDYPGNFDTSSR	   G	   14 0.85 0.93 0.33 0.61 0.01 0.33 1 1 1 1 1 2 3 4
4 P47930	   PAp00068948	  R	   GSSGSPAHAESYSSGGGGQQK	   F	   21 0.85 0.85 0.36 0.78 0.01 0.34 1 1 1 1 1 2 3 4
6 P47930	   	  	   R	   SHPYSPLPGLASVPGHMALPRPGVIK	   T	   26 0.73 0.8 0.22 0.68 0 -­‐0.05 1 1 1 1 1 2 9 4
7 P47930	   	  	   K	   QEPPEEDSPSSSAGMDK	   T	   17 0.72 0.67 0.25 0.62 0.01 0.76 1 1 1 1 1 2 0 4
8 P47930	   PAp00583339	  K	   LEFMLVAHGPVCK	   I	   13 0.41 0.53 0.19 0.5 0.06 -­‐0.19 1 1 1 1 1 1 9 3
10 P47930	   	  	   K	   TIGTTVGR	   R	   8 0.07 0.02 0.38 0.67 0 0.28 1 1 1 1 1 2 9 4
12 P47930	   	  	   R	   VDMPGSGSAFIPTINAITTSQDLQWMVQPTVITSMSNPYPR	   S	   41 0.04 0 0.1 0.44 0 -­‐0.03 1 1 1 1 1 2 6 4
14 P47930	   	  	   K	   ISPEER	   R	   6 0.03 0.01 0.11 0.08 0.01 0.05 2 4 4 8 3 6 9 18
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10 P97863	   PAp01440781	  K	   SGVFNVSELVR	   V	   11 0.82 0.77 0.66 0.7 0.02 0.38 1 3 3 9 1 6 14 18 38160000 1 3
8 P97863	   PAp00512036	  K	   NPPGYLEDSFVK	   S	   12 0.86 0.77 0.79 0.67 0.01 0.95 1 3 3 9 1 6 14 18 31199000 2 2
16 P97863	   PAp00518239	  R	   TPPPPSPLPFPTQAILPPAPSSYFSHPTIR	   Y	   30 0.16 0.23 0.33 0.66 0 0.37 1 3 3 8 1 5 17 16 19483000 4 1
3 P97863	   PAp00779301	  K	   GIPLESTDGER	   L	   11 0.9 0.89 0.84 0.7 0.04 0.59 4 20 20 32 4 30 70 82 19467000 5 1
11 P97863	   PAp00411071	  R	   YPPHLNPQDTLK	   N	   12 0.8 0.78 0.42 0.6 0 0.73 1 3 3 8 1 5 17 16 7370200 7 4 2
12 P97863	   PAp00482053	  K	   KPEKPLFSSTSPQDSSPR	   L	   18 0.8 0.9 0.32 0.54 0.04 -­‐0.32 1 3 3 9 1 6 0 18 8142100 6
15 P97863	   PAp00482211	  R	   TPITQGTGVNFPIGEIPSQPYYHDMNSGVNLQR	   S	   33 0.52 0.58 0.19 0.63 0.01 0.26 1 3 3 9 1 5 14 17 2442100 9
24 P97863	   PAp00483889	  K	   HPCCVLSNPDQK	   G	   12 0.04 0 0.28 0.44 0.05 -­‐0.68 1 3 3 10 1 7 17 20 1492900 10
17 P97863	   PAp00762739	  R	   LDLVMVILFK	   G	   10 0.11 0.11 0.26 0.68 0.02 0.27 4 20 20 32 4 30 70 82 1484200 11
5 P97863	   	  	   K	   TISIDENMEPSPTGDFYPSPNSPAAGSR	   T	   28 0.89 0.96 0.51 0.66 0 0.66 1 3 3 9 1 6 0 18 841470 13
1 P97863	   	  	   R	   TPILPANVQNYGLNIIGEPFLQAETSN	   -­‐	   27 0.91 0.96 0.05 0.73 0.02 1.01 1 2 2 5 1 3 7 10
2 P97863	   	  	   R	   EDFVLTVTGK	   K	   10 0.9 0.86 0.72 0.71 0.05 0.76 2 10 10 20 2 17 34 47
4 P97863	   	  	   K	   NYVPSYDPSSPQTSQPNSSGQVVGK	   V	   25 0.89 0.98 0.45 0.65 0.01 0.51 1 1 1 4 1 3 0 8
6 P97863	   	  	   R	   DPSFLHQQQLR	   I	   11 0.89 0.86 0.39 0.54 0.12 0.23 1 1 1 3 1 2 5 6
7 P97863	   PAp01152716	  R	   LSTFPQHHHPGIPGVAHSVISTR	   T	   23 0.88 0.97 0.23 0.77 0 0.2 1 3 3 9 1 6 17 18
9 P97863	   PAp00526319	  K	   ELDLFLAYYVQEQDSGQSGSPSHSDPAK	   N	   28 0.85 0.9 0.4 0.56 0.01 0.6 1 3 3 9 1 7 1 19
13 P97863	   PAp00778994	  R	   AIAYTWFNLQAR	   K	   12 0.62 0.68 0.22 0.67 0 0.07 1 3 3 10 1 7 16 20
14 P97863	   PAp00513281	  K	   DELLSEKPEIK	   Q	   11 0.61 0.68 0.51 0.31 0.05 0.21 1 3 3 10 1 7 17 20
18 P97863	   	  	   K	   SPHCTNPALCVQPHHITVSVK	   E	   21 0.09 0.12 0.31 0.66 0.06 -­‐0.56 1 3 3 9 1 7 17 19
19 P97863	   	  	   R	   HLYPSTSEDTLGITWQSPGTWASLVPFQVSNR	   T	   32 0.07 0.1 0.09 0.61 0 -­‐0.01 1 2 2 5 1 3 7 10
20 P97863	   	  	   R	   DQDMSSPTTMK	   K	   11 0.06 0.01 0.25 0.56 0.01 0.38 1 3 3 9 1 6 17 18
21 P97863	   	  	   R	   YVGLSPR	   D	   7 0.06 0.05 0.31 0.2 0.08 0.16 1 1 1 4 1 3 7 8
22 P97863	   	  	   R	   ICDWTMNQNGR	   H	   11 0.06 0.02 0.24 0.55 0.06 -­‐0.59 1 2 2 5 1 3 7 10
23 P97863	   	  	   R	   SLSSPPSSK	   R	   9 0.05 0 0.21 0.3 0.01 0.34 1 3 3 9 1 6 17 18
25 P97863	   	  	   -­‐	   MMYSPICLTQDEFHPFIEALLPHVR	   A	   25 0.04 0.02 0.05 0.42 0 -­‐0.41 1 3 3 5 1 5 15 13
Proteotypic	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4 Q505F1	   	  	   R	   SPLAATPTFVTDSETAR	   S	   17 0.93 0.86 0.71 0.69 0.14 0.81 1 2 2 3 1 3 0 8 30690000 1 1
6 Q505F1	   	  	   K	   AYVEFQDYITR	   T	   11 0.92 0.9 0.24 0.69 0.14 0.3 1 1 1 3 1 2 0 6 17958000 2 2
26 Q505F1	   	  	   R	   AFDTLAK	   A	   7 0.06 0.02 0.29 0.36 0.04 0.47 2 2 2 5 2 4 20 11 8729600 3 3
21 Q505F1	   	  	   K	   GLIGNVR	   I	   7 0.09 0.1 0.46 0.46 0.03 0.28 1 1 1 3 1 2 0 6 4016500 4 4
3 Q505F1	   	  	   K	   EGPLLSESHVAFR	   L	   13 0.94 0.98 0.8 0.72 0.14 0.68 1 1 1 3 1 2 0 6 3445800 5 1
22 Q505F1	   	  	   K	   VFDLCVVCGDK	   A	   11 0.08 0 0.33 0.79 0.08 -­‐0.59 1 2 2 3 1 3 9 8 2228400 6 5
32 Q505F1	   	  	   K	   NLVYSCR	   G	   7 0.04 0.01 0.24 0.41 0.02 -­‐0.64 1 2 2 3 1 3 11 8 1975700 7
1 Q505F1	   	  	   K	   QFILANHEGSTPGK	   V	   14 0.95 0.98 0.78 0.69 0.17 0.95 1 2 2 3 1 3 0 8 1013700 8
19 Q505F1	   	  	   R	   IDSVIPHILK	   M	   10 0.44 0.3 0.43 0.45 0.14 0.56 1 1 1 3 1 2 5 6 486940 9
23 Q505F1	   	  	   R	   TYPDDTYR	   L	   8 0.07 0.03 0.25 0.59 0.03 0.15 1 1 1 3 1 2 5 6 323440 10
24 Q505F1	   	  	   K	   LQEFCNSMVK	   L	   10 0.07 0.05 0.25 0.46 0.09 -­‐0.46 1 1 1 3 1 2 4 6 111760 11
2 Q505F1	   	  	   K	   IQIVTALDHSTQGK	   Q	   14 0.94 0.98 0.67 0.78 0.13 0.82 1 2 2 3 1 3 0 8
5 Q505F1	   	  	   R	   SAGLLDSGMFVNIHPSGIK	   T	   19 0.92 0.97 0.23 0.74 0.08 0.61 1 1 1 3 1 2 0 6
7 Q505F1	   	  	   K	   AIVLFSPDHPGLENMELIER	   F	   20 0.9 0.92 0.05 0.67 0.04 0.99 1 1 1 3 1 2 0 6
8 Q505F1	   	  	   K	   DLSHCGGDMPVVQSLR	   N	   16 0.9 0.93 0.6 0.7 0.1 -­‐0.32 1 1 1 3 1 2 0 6
9 Q505F1	   	  	   R	   NGDTSFGAFHHDIQTNGDVSR	   A	   21 0.89 0.79 0.32 0.72 0.11 0.5 1 1 1 3 1 2 0 6
10 Q505F1	   	  	   R	   LTMPSPMPEYLNVHYIGESASR	   L	   22 0.88 0.95 0.11 0.65 0.03 0.42 1 1 1 3 1 2 11 6
11 Q505F1	   	  	   K	   VFLTTPDAAGVNQLFFTSPDLSAPHLQLLTEK	   S	   32 0.85 0.91 0.04 0.75 0 0.42 1 2 2 3 1 3 0 8
12 Q505F1	   PAp00773122	  R	   LMNATITEELFFK	   G	   13 0.84 0.8 0.13 0.63 0.06 0.53 1 1 1 3 1 2 5 6
13 Q505F1	   	  	   K	   ALTPGESSACQSPEEGMEGSPHLIAGEPSFVEK	   E	   33 0.72 0.76 0.62 0.57 0 0.11 1 1 1 3 1 1 0 5
14 Q505F1	   	  	   K	   LCIDGHEYAYLK	   A	   12 0.64 0.55 0.16 0.6 0.14 -­‐0.28 1 1 1 3 1 2 0 6
15 Q505F1	   	  	   K	   TEPAMLMAPDK	   A	   11 0.63 0.6 0.65 0.46 0.02 0.69 1 1 1 3 1 2 0 6
16 Q505F1	   	  	   K	   AESCQGDLSTLASVVTSLANLGK	   A	   23 0.6 0.67 0.2 0.71 0 -­‐0.09 1 1 1 3 1 2 0 6
17 Q505F1	   	  	   K	   MEPADYNSQIIGHSL	   -­‐	   15 0.57 0.96 0.61 -­‐1 0.05 1.64 1 1 1 3 1 2 0 6
18 Q505F1	   	  	   -­‐	   MATIEEIAHQIIDQQMGEIVTEQQTGQK	   I	   28 0.55 0.59 0.26 0.56 0.02 0.35 1 2 2 3 1 3 0 8
20 Q505F1	   	  	   K	   SLMEHIFK	   L	   8 0.13 0.3 0.13 0.28 0.03 0.29 1 1 1 3 1 2 0 6
25 Q505F1	   	  	   R	   HYGAITCEGCK	   G	   11 0.06 0 0.19 0.67 0.09 -­‐0.77 1 2 2 3 1 3 0 8
27 Q505F1	   	  	   K	   SSNCAASTEK	   I	   10 0.06 0.03 0.18 0.63 0.02 -­‐0.24 1 2 2 3 1 3 9 8
28 Q505F1	   	  	   R	   LLFLSMHWALSIPSFQALGQENSISLVK	   A	   28 0.05 0.01 0.02 0.65 0 -­‐0.1 1 1 1 3 1 2 10 6
29 Q505F1	   	  	   K	   SPDQGPNK	   V	   8 0.05 0 0.13 0.37 0.01 0.35 1 2 2 3 1 3 0 8
30 Q505F1	   	  	   K	   QDSVQCER	   K	   8 0.05 0 0.21 0.64 0 -­‐0.46 1 2 2 3 1 3 9 8
31 Q505F1	   	  	   R	   CIAFGMK	   Q	   7 0.04 0.01 0.38 0.33 0.01 -­‐0.23 1 2 2 3 1 3 9 8
33 Q505F1	   	  	   K	   DCVINK	   H	   6 0.04 0 0.2 0.26 0.02 -­‐0.37 1 2 2 3 1 3 0 8
34 Q505F1	   	  	   K	   AYWNELFTLGLAQCWQVMNVATILATFVNCLHSSLQQDK	   M	   39 0.03 0 0.01 0.53 0 -­‐0.98 1 1 1 3 1 2 0 6
35 Q505F1	   	  	   R	   KPIEVSR	   E	   7 0.03 0.01 0.17 0.21 0.01 -­‐0.46 1 2 2 3 1 3 9 8
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9 O54714	   PAp00442507	  R	   VSSIVAPGSSLR	   E	   12 0.88 0.87 0.83 0.77 0.01 0.34 1 3 3 4 1 4 0 11 3787000 1 2
1 O54714	   PAp01526813	  K	   LTADPDSEVATTSLR	   V	   15 0.94 0.98 0.83 0.78 0.08 0.93 1 3 3 5 1 4 5 12 3032300 2 4
7 O54714	   	  	   R	   FEEAHFTFALTPQQLQQILTSR	   E	   22 0.9 0.99 0.1 0.74 0.04 0.26 1 3 3 5 1 5 0 13 2822600 4 1
2 O54714	   	  	   K	   GALTSGHQPSSVLR	   S	   14 0.93 0.97 0.7 0.85 0.06 0.43 1 3 3 4 1 4 0 11 2537800 5 8 2
11 O54714	   PAp01528643	  R	   LSATVPNTIVVNWSSEFGR	   N	   19 0.85 0.83 0.08 0.77 0.05 0.33 1 3 3 5 1 5 9 13 2456100 6 3 4
6 O54714	   	  	   R	   NYSLSVYLVR	   Q	   10 0.9 0.8 0.37 0.67 0.17 0.09 1 3 3 5 1 5 5 13 1369700 7 5
4 O54714	   PAp01534241	  R	   EGHGGPLPSGPSLTGCR	   S	   17 0.91 0.85 0.5 0.78 0.14 -­‐0.04 1 3 3 4 1 4 5 11 805050 8 3
17 O54714	   	  	   K	   CDYTIQVQLR	   F	   10 0.14 0.06 0.36 0.65 0.15 -­‐0.57 1 3 3 5 1 5 9 13 573440 9 7
12 O54714	   	  	   K	   TLGPSDLSLLSLPPGTSPVGSPGPLAPIPPTLLTPGTLLGPK	   R	   42 0.84 0.92 0.35 0.58 0 0.37 1 2 2 3 1 3 0 8 5
3 O54714	   	  	   R	   VSELQVLLGFAGR	   N	   13 0.92 0.91 0.43 0.72 0.13 0.36 2 8 8 10 2 10 22 28 1
24 O54714	   	  	   K	   ALHLLK	   S	   6 0.05 0.02 0.22 0.08 0.06 0.29 3 9 9 13 3 11 33 33 6
30 O54714	   	  	   R	   LTVPCR	   A	   6 0.03 0 0.29 0.18 0.03 -­‐0.48 2 4 4 6 2 5 5 15 2851300 3
5 O54714	   	  	   R	   GTPSHFLGPLAPTLGSSHR	   S	   19 0.9 0.99 0.37 0.72 0.02 0.45 1 3 3 4 1 4 0 11
8 O54714	   	  	   K	   HCPVTSAAIPALPGSK	   G	   16 0.88 0.82 0.78 0.61 0.11 0.03 1 3 3 4 1 4 0 11
10 O54714	   	  	   R	   VEVIDLTIESSSDEEDLPPTK	   K	   21 0.88 0.95 0.24 0.49 0 1.19 1 3 3 4 1 4 5 11
13 O54714	   	  	   K	   EASEVCPPPGYGLDGLQYSAVQEGIQPESK	   K	   30 0.82 0.91 0.45 0.53 0.01 0.18 1 3 3 4 1 4 0 11
14 O54714	   	  	   R	   QLTAGTLLQK	   L	   10 0.78 0.6 0.68 0.66 0.09 0.42 1 3 3 5 1 5 5 13
15 O54714	   PAp01534969	  K	   RPSRPINITPLAR	   L	   13 0.74 0.94 0.31 0.63 0 -­‐0.97 1 3 3 5 1 5 9 13
16 O54714	   	  	   K	   LCPLPGYLPPTK	   N	   12 0.22 0.23 0.45 0.39 0.13 0.01 1 3 3 5 1 5 9 13
18 O54714	   	  	   R	   ALTCAHLQSFDAALYLQMNEK	   K	   21 0.08 0.24 0.08 0.54 0 -­‐0.39 1 3 3 5 1 4 5 12
19 O54714	   	  	   R	   SSTPAPPPGR	   V	   10 0.06 0.08 0.28 0.37 0 0.45 1 3 3 4 1 4 0 11
20 O54714	   PAp00857048	  -­‐	   MAELGELK	   H	   8 0.06 0.04 0.55 0.36 0 0.45 1 2 2 2 1 3 6 7
21 O54714	   PAp00138136	  K	   KPTWTCPVCDK	   K	   11 0.06 0 0.29 0.66 0.09 -­‐1.12 1 3 3 5 1 4 5 12
22 O54714	   	  	   R	   EVLPGAK	   C	   7 0.05 0.01 0.21 0.27 0.03 0.57 2 5 5 6 2 7 13 18
23 O54714	   	  	   K	   SSCAPSVQMK	   I	   10 0.05 0.01 0.33 0.39 0.04 -­‐0.36 1 3 3 6 1 5 10 14
25 O54714	   	  	   R	   VSLMCPLGK	   M	   9 0.05 0.01 0.49 0.24 0.04 -­‐0.22 2 8 8 9 2 9 18 26
26 O54714	   	  	   R	   FCLCETSCPQEDYFPPNLFVK	   V	   21 0.04 0 0.13 0.69 0.01 -­‐0.82 1 3 3 5 1 5 9 13
27 O54714	   	  	   K	   HELLAK	   A	   6 0.04 0.02 0.16 0.15 0.01 0.32 1 3 3 6 1 6 10 15
28 O54714	   	  	   K	   HMVMSFR	   V	   7 0.04 0.01 0.19 0.17 0.04 -­‐0.08 1 2 2 2 1 3 6 7
29 O54714	   	  	   K	   NGAEPK	   R	   6 0.04 0 0.03 0.06 0.03 0.3 1 3 3 5 1 5 9 13
31 O54714	   	  	   R	   NPDHSR	   A	   6 0.03 0 0.05 0.09 0.01 -­‐0.02 3 9 9 12 3 11 23 32
32 O54714	   	  	   K	   APYESLIIDGLFMEILNSCSDCDEIQFMEDGSWCPMKPK	   K	   39 0.03 0 0.05 0.37 0 -­‐0.99 1 3 3 5 1 4 0 12
33 O54714	   	  	   R	   SDVISLD	   -­‐	   7 0.03 0.04 0.34 -­‐1 0.06 1.11 1 3 3 4 1 4 0 11
34 O54714	   	  	   R	   EVDMHPPLPQPVHPDVTMKPLPFYEVYGELIRPTTLASTSSQR	   F	   43 0.02 0.01 0.18 -­‐1 0 -­‐0.35 1 2 2 3 1 3
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20 Q9JM05	   PAp02039137	  R	   VSLICPLVK	   M	   9 0.06 0.05 0.37 0.31 0.07 -­‐0.12 1 1 1 1 1 2 3 4 11113000 1 4
11 Q9JM05	   PAp02039138	  K	   LQESPCIFALTPR	   Q	   13 0.5 0.49 0.65 0.52 0.09 -­‐0.3 1 1 1 2 1 2 3 5 8903900 3 2
10 Q9JM05	   PAp02039139	  K	   SYSVALYLVR	   Q	   10 0.52 0.36 0.38 0.68 0.13 0.09 1 1 1 3 1 3 3 7 8281900 4 1
1 Q9JM05	   	  	   R	   TPLSGPTVDYPVLYGK	   Y	   16 0.94 0.97 0.58 0.8 0.12 0.75 1 1 1 2 1 2 0 5 7449100 5 6
17 Q9JM05	   	  	   K	   AVQVVLR	   I	   7 0.07 0.03 0.34 0.47 0.04 0.18 1 1 1 2 1 2 3 5 7087600 7 5
3 Q9JM05	   PAp02039136	  R	   ITVTWGNYGK	   S	   10 0.88 0.78 0.42 0.68 0.11 0.33 1 1 1 3 1 3 3 7 4887800 10 7
27 Q9JM05	   	  	   R	   LSVPCR	   A	   6 0.04 0.01 0.24 0.13 0.06 -­‐0.54 1 1 1 2 2 3 3 6 4345200 11 3
16 Q9JM05	   	  	   K	   ILSECEGADEIEFLAEGSWRPIR	   A	   23 0.07 0.19 0.09 0.52 0.03 -­‐0.68 1 1 1 1 1 1 0 3 3452300 13 1
15 Q9JM05	   PAp01098572	  R	   ICYSDTSCPQEDQYPPNIAVK	   V	   21 0.07 0.09 0.24 0.57 0.05 -­‐0.45 1 1 1 2 1 2 3 5 607960 18 2
6 Q9JM05	   	  	   R	   QLTSSDLLQR	   L	   10 0.82 0.6 0.6 0.74 0.13 0.17 1 1 1 3 1 3 0 7 9916700 2
7 Q9JM05	   PAp00533715	  R	   ALQLVQFDCSPELFK	   K	   15 0.78 0.66 0.2 0.54 0.16 -­‐0.16 1 1 1 2 1 2 3 5 3462400 12
19 Q9JM05	   	  	   K	   YLNGLGR	   L	   7 0.06 0.05 0.36 0.29 0.06 0.14 1 1 1 2 1 2 3 5 2070400 15
5 Q9JM05	   PAp00747750	  R	   VSDLQMLLGFVGR	   S	   13 0.86 0.83 0.22 0.68 0.08 0.27 1 1 1 2 1 2 3 5 838390 16
2 Q9JM05	   PAp01542659	  R	   LDPDSEIATTGVR	   V	   13 0.94 0.95 0.94 0.75 0.07 0.98 1 1 1 1 1 2 3 4
4 Q9JM05	   	  	   K	   SAEPGPQAPRPLDPLALHSMPR	   T	   22 0.88 0.93 0.48 0.64 0.04 0.12 1 1 1 2 1 2 0 5
8 Q9JM05	   	  	   K	   LPFFNMLDELLKPTELVPQSAEK	   L	   23 0.76 0.76 0.14 0.72 0.01 0.32 1 1 1 2 1 2 0 5
9 Q9JM05	   PAp00501989	  K	   VNHSYCSVPGYYPSNKPGVEPK	   R	   22 0.66 0.7 0.34 0.46 0.09 -­‐0.45 1 1 1 2 1 2 3 5
12 Q9JM05	   	  	   -­‐	   MAAELVEAK	   N	   9 0.19 0.21 0.58 0.4 0.06 0.56 1 1 1 2 1 2 3 5
13 Q9JM05	   	  	   K	   TGADVVDLTLDSSSSSEDEDEDEDDDEDEDEGPRPK	   R	   36 0.13 0.24 0.34 0.43 0 0.62 1 1 1 1 1 1 0 3
14 Q9JM05	   	  	   K	   GLVPAC	   -­‐	   6 0.1 0.01 0.45 0.7 0.04 0.36 1 1 1 1 1 1 3 3
18 Q9JM05	   	  	   R	   QVEMIR	   N	   6 0.06 0.02 0.29 0.68 0.01 -­‐0.07 2 2 2 3 2 3 10 8
21 Q9JM05	   	  	   K	   ELYETR	   Y	   6 0.06 0.01 0.09 0.7 0 -­‐0.04 1 1 1 2 1 2 3 5
22 Q9JM05	   	  	   K	   HELVTR	   A	   6 0.04 0.03 0.11 0.16 0.05 0.03 1 1 1 2 1 2 3 5
23 Q9JM05	   	  	   K	   RPCRPINLTHLMYLSSATNR	   I	   20 0.04 0.08 0.18 0.73 0.01 -­‐1.66 1 1 1 2 1 2 3 5
24 Q9JM05	   	  	   R	   ELQPGVK	   A	   7 0.04 0.04 0.15 0.15 0 0.45 1 1 1 2 1 2 3 5
25 Q9JM05	   PAp02039140	  R	   AETCAHLQCFDAVFYLQMNEK	   K	   21 0.04 0.03 0.05 0.47 0.04 -­‐0.85 1 1 1 1 1 1 3 3
26 Q9JM05	   	  	   K	   NMVMSFR	   V	   7 0.04 0.01 0.25 0.23 0.01 -­‐0.05 1 1 1 2 1 2 3 5
28 Q9JM05	   	  	   K	   KPTWMCPVCDKPAAYDQLIIDGLLSK	   I	   26 0.03 0 0.11 0.62 0.01 -­‐1.38 1 1 1 1 1 1 0 3
29 Q9JM05	   	  	   K	   TLKPEVR	   L	   7 0.03 0.02 0.22 0.2 0 -­‐0.44 1 1 1 2 1 2 3 5
30 Q9JM05	   	  	   K	   HPELCK	   A	   6 0.03 0.01 0.08 0.07 0.02 -­‐0.4 1 1 1 3 1 3 3 7
Proteotypic	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1 P37238	   PAp00732267	  R	   SVEAVQEITEYAK	   N	   13 0.95 0.97 0.72 0.81 0.13 0.91 1 2 2 2 1 3 11 7 24270000 1 1
4 P37238	   PAp00892316	  K	   LLAEISSDIDQLNPESADLR	   A	   20 0.9 0.99 0.1 0.62 0 1.03 1 2 2 2 1 4 15 8 3060000 3 2 1
21 P37238	   	  	   R	   IFQGCQFR	   S	   8 0.05 0.02 0.26 0.48 0.03 -­‐0.52 1 2 2 2 1 3 11 7 2658200 4 4
7 P37238	   	  	   K	   VEPASPPYYSEK	   T	   12 0.84 0.67 0.51 0.61 0.1 0.71 1 2 2 2 1 4 20 8 2360500 5 3
17 P37238	   	  	   K	   HLYDSYIK	   S	   8 0.08 0.1 0.13 0.26 0.09 0.26 1 2 2 2 1 4 16 8 2360400 6 5
5 P37238	   PAp01530640	  K	   LNHPESSQLFAK	   V	   12 0.88 0.92 0.58 0.64 0.01 0.68 1 2 2 2 1 3 11 7 1463900 8 6
9 P37238	   	  	   K	   NIPGFINLDLNDQVTLLK	   Y	   18 0.65 0.56 0.06 0.65 0.04 0.87 1 2 2 2 1 3 0 7 0 11 7
15 P37238	   	  	   K	   HITPLQEQSK	   E	   10 0.15 0.11 0.41 0.56 0.07 0.49 1 2 2 2 1 3 11 7 3179100 2
6 P37238	   	  	   R	   QIVTEHVQLLHVIK	   K	   14 0.85 0.71 0.27 0.63 0.13 0.43 1 2 2 2 1 3 0 7 2042400 7
2 P37238	   PAp01540877	  K	   DGVLISEGQGFMTR	   E	   14 0.94 0.98 0.8 0.79 0.14 0.54 1 2 2 2 1 3 11 7 846270 9
20 P37238	   	  	   K	   FEFAVK	   F	   6 0.05 0.04 0.35 0.3 0 0.37 2 3 3 3 2 4 24 10 829700 10
3 P37238	   PAp01537570	  K	   TETDMSLHPLLQEIYK	   D	   16 0.91 0.91 0.25 0.68 0.07 0.95 1 2 2 2 1 3 11 7
8 P37238	   	  	   R	   KPFGDFMEPK	   F	   10 0.68 0.62 0.46 0.56 0.08 -­‐0.02 1 2 2 2 1 3 11 7
10 P37238	   	  	   R	   ADPMVADYK	   Y	   9 0.46 0.41 0.59 0.65 0.03 0.59 1 2 2 2 1 4 0 8
11 P37238	   	  	   K	   SPFVIYDMNSLMMGEDK	   I	   17 0.32 0.32 0.07 0.67 0.05 0.56 1 2 2 2 1 3 11 7
12 P37238	   	  	   K	   TQLYNRPHEEPSNSLMAIECR	   V	   21 0.22 0.42 0.26 0.66 0.04 -­‐0.92 1 2 2 2 1 4 0 8
13 P37238	   	  	   K	   LQEYQSAIK	   V	   9 0.17 0.25 0.51 0.35 0.06 0.34 1 2 2 2 1 4 20 8
14 P37238	   	  	   K	   ASGFHYGVHACEGCK	   G	   15 0.16 0.07 0.23 0.73 0.17 -­‐0.74 4 5 5 7 4 7 38 19
16 P37238	   	  	   K	   CLAVGMSHNAIR	   F	   12 0.09 0.14 0.42 0.69 0.02 -­‐0.47 1 2 2 2 1 4 14 8
18 P37238	   	  	   K	   YGVHEIIYTMLASLMNK	   D	   17 0.08 0.08 0.04 0.69 0 0.23 1 2 2 2 1 3 11 7
19 P37238	   	  	   R	   AILTGK	   T	   6 0.05 0.02 0.33 0.26 0.02 0.42 3 4 4 4 3 9 25 17
22 P37238	   	  	   K	   SFPLTK	   A	   6 0.04 0.01 0.18 0.2 0.03 0.31 1 2 2 2 1 5 17 9
23 P37238	   	  	   R	   MPQAEK	   E	   6 0.03 0.01 0.07 0.06 0.01 0.16 3 6 6 5 3 9 15 20
24 P37238	   	  	   R	   CDLNCR	   I	   6 0.03 0 0.12 0.16 0.03 -­‐1.04 1 2 2 2 1 4 17 8
25 P37238	   	  	   K	   FNALELDDSDLAIFIAVIILSGDRPGLLNVKPIEDIQDNLLQALELQLK	   L	   49 0.02 0 -­‐1 -­‐1 0 -­‐0.02 1 2 2 2 1 3 11 7
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16 P18911	   PAp00409025	  R	   GLGQPDLPK	   E	   9 0.08 0.04 0.39 0.33 0.05 0.66 1 1 1 2 1 2 5 5 4498200 3 1
9 P18911	   PAp01528542	  K	   LQEPLLEALR	   L	   10 0.81 0.72 0.6 0.51 0.08 0.42 1 3 3 2 1 3 10 8 7300400 1 2
18 P18911	   	  	   K	   FSELATK	   C	   7 0.05 0.07 0.21 0.25 0.02 0.36 2 7 7 5 2 7 25 19 3495900 5 3
12 P18911	   	  	   R	   VQLDLGLWDK	   F	   10 0.44 0.44 0.44 0.55 0.04 0.48 1 3 3 2 1 3 12 8 1161900 7 4
1 P18911	   PAp01540409	  R	   LPGFTGLSIADQITLLK	   A	   17 0.93 0.98 0.18 0.76 0.1 0.6 1 3 3 2 1 3 13 8 378120 11 5
15 P18911	   PAp00164554	  K	   SSGYHYGVSSCEGCK	   G	   15 0.13 0.05 0.24 0.71 0.16 -­‐0.73 1 3 3 3 1 4 9 10 1233300 6 6 1
23 P18911	   	  	   R	   VYKPCFVCNDK	   S	   11 0.04 0 0.29 0.39 0.08 -­‐1.18 1 3 3 3 1 4 10 10 3934600 4 7 2
6 P18911	   	  	   R	   LFAPGALGPGSGYPGAGFPFAFPGALR	   G	   27 0.86 0.86 0.27 0.87 0.02 0.19 1 1 1 2 1 2 0 5 3
19 P18911	   	  	   K	   IVEFAK	   R	   6 0.05 0.02 0.38 0.21 0 0.41 2 7 7 5 2 7 24 19 5391100 2
17 P18911	   	  	   K	   AACLDILMLR	   I	   10 0.06 0 0.33 0.5 0.07 -­‐0.35 1 3 3 2 1 3 13 8 452460 10
2 P18911	   	  	   R	   YTPEQDTMTFSDGLTLNR	   T	   18 0.91 0.96 0.21 0.72 0.06 0.66 3 9 9 11 3 9 41 29
3 P18911	   PAp01540098	  K	   EEGSPDSYELSPQLEELITK	   V	   20 0.9 0.96 0.37 0.63 0 1.01 1 3 3 3 1 4 12 10
4 P18911	   PAp00895734	  R	   GSPPFEMLSPSFR	   G	   13 0.89 0.96 0.65 0.49 0.05 0.41 1 1 1 2 1 2 5 5
5 P18911	   	  	   K	   AHQETFPSLCQLGK	   Y	   14 0.88 0.88 0.61 0.65 0.11 -­‐0.26 2 7 7 6 2 8 25 21
7 P18911	   PAp00444381	  K	   MEIPGPMPPLIR	   E	   12 0.84 0.74 0.49 0.54 0.1 0.44 1 3 3 2 1 3 10 8
8 P18911	   	  	   K	   EMASLSVETQSTSSEEMVPSSPSPPPPPR	   V	   29 0.81 0.87 0.54 0.4 0.02 0.5 1 1 1 2 1 2 5 5
10 P18911	   	  	   R	   EMLENPEMFEDDSSKPGPHPK	   A	   21 0.77 0.83 0.51 0.34 0.03 0.43 1 3 3 2 1 3 0 8
11 P18911	   	  	   K	   ASSEDEAPGGQGK	   R	   13 0.54 0.52 0.16 0.58 0.04 0.61 1 3 3 2 1 3 0 8
13 P18911	   	  	   K	   YTTNSSADHR	   V	   10 0.3 0.26 0.12 0.63 0.11 0.15 2 7 7 6 2 8 24 21
14 P18911	   	  	   R	   RPSQPYMFPR	   M	   10 0.19 0.46 0.34 0.45 0.01 -­‐0.58 1 3 3 2 1 3 10 8
20 P18911	   	  	   K	   NMVYTCHR	   D	   8 0.04 0 0.15 0.55 0.04 -­‐0.71 2 5 5 8 2 6 25 19
21 P18911	   	  	   K	   CFEVGMSK	   E	   8 0.04 0.01 0.25 0.41 0.03 -­‐0.41 2 7 7 6 2 8 38 21
22 P18911	   	  	   R	   MDLEEPEK	   V	   8 0.04 0.02 0.34 0.13 0 0.37 1 3 3 2 1 3 10 8
24 P18911	   	  	   K	   NCIINK	   V	   6 0.03 0 0.26 0.13 0.01 -­‐0.33 2 5 5 9 2 6 25 20
25 P18911	   	  	   R	   GQSPQPDQGP	   -­‐	   10 0.02 0.01 0.28 -­‐1 0.03 0.92 1 3 3 2 1 3 0 8
26 P18911	   	  	   R	   TQMHNAGFGPLTDLVFAFAGQLLPLEMDDTETGLLSAICLICGDR	   M	   45 0.02 0 0.01 -­‐1 0 -­‐0.69 1 3 3 2 1 3 10 8
Proteotypic	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7 P28700	   	  	   K	   HFLPLDFSTQVNSSSLNSPTGR	   G	   22 0.89 0.98 0.18 0.66 0.04 0.38 1 1 1 2 1 1 0 4 26781000 2 10 1
6 P28700	   PAp00747855	   R	   AGWNELLIASFSHR	   S	   14 0.9 0.94 0.26 0.52 0.11 0.2 3 4 4 12 3 8 39 24 20517000 3 4 4
2 P28700	   PAp00746849	   K	   ILEAELAVEPK	   T	   11 0.94 0.84 0.66 0.58 0.23 0.9 2 2 2 8 2 5 7 15 20343000 4 3
3 P28700	   PAp01449315	   K	   GLSNPAEVEALR	   E	   12 0.94 0.96 0.93 0.74 0.08 0.75 1 1 1 4 1 3 4 8 18740000 5 2
10 P28700	   PAp01926880	   R	   AIVLFNPDSK	   G	   10 0.79 0.69 0.85 0.34 0.07 0.7 1 1 1 4 1 3 4 8 16150000 7 1
1 P28700	   PAp00752323	   R	   NSAHSAGVGAIFDR	   V	   14 0.95 0.85 0.69 0.85 0.24 0.52 2 3 3 8 2 6 42 17 8635300 8 6 2
18 P28700	   	  	   R	   VLTELVSK	   M	   8 0.08 0.04 0.41 0.48 0.03 0.42 3 4 4 12 3 8 45 24 8107900 10 5
15 P28700	   PAp01926875	   K	   VYASLEAYCK	   H	   10 0.08 0.05 0.38 0.52 0.09 -­‐0.33 1 1 1 4 1 3 4 8 4544800 14 7
16 P28700	   PAp00029245	   K	   CLEHLFFFK	   L	   9 0.08 0 0.14 0.34 0.16 -­‐0.26 3 4 4 12 3 8 39 24 3409500 16 9 5
14 P28700	   PAp00010394	   K	   HYGVYSCEGCK	   G	   11 0.08 0 0.17 0.66 0.14 -­‐0.81 3 4 4 14 3 9 47 27 1128800 21 11
8 P28700	   PAp00606610	   R	   IPHFSELPLDDQVILLR	   A	   17 0.89 0.91 0.13 0.63 0.05 0.75 1 1 1 4 1 3 4 8 42668000 1 8 3
13 P28700	   PAp00745638	   K	   QLFTLVEWAK	   R	   10 0.36 0.36 0.18 0.71 0.05 0.28 3 4 4 12 3 8 46 24 17025000 6
5 P28700	   PAp01791977	   K	   VPAHPSGNMASFTK	   H	   14 0.92 0.97 0.6 0.69 0.04 0.69 1 1 1 5 1 4 4 10 8514500 9
11 P28700	   	  	   R	   NENEVESTSSANEDMPVEK	   I	   19 0.7 0.7 0.37 0.47 0.01 0.78 1 1 1 4 1 3 0 8 6568800 11
9 P28700	   PAp01926882	   K	   DGILLATGLHVHR	   N	   13 0.87 0.89 0.43 0.58 0.05 0.45 3 4 4 12 3 8 39 24 5716300 13
12 P28700	   PAp01926887	   K	   TETYVEANMGLNPSSPNDPVTNICQAADK	   Q	   29 0.52 0.55 0.41 0.67 0.01 0.21 1 1 1 4 1 3 4 8 3176600 17
19 P28700	   PAp01926868	   K	   TELGCLR	   A	   7 0.04 0.02 0.3 0.5 0.01 -­‐0.62 2 3 3 8 2 6 42 17 2345200 18
23 P28700	   PAp01638909	   K	   DLTYTCR	   D	   7 0.04 0.01 0.2 0.35 0.02 -­‐0.67 1 1 1 5 1 4 4 10 1264100 20
4 P28700	   	  	   K	   LIGDTPIDTFLMEMLEAPHQAT	   -­‐	   22 0.93 0.99 0.05 0.75 0.04 1.43 1 1 1 4 1 3 0 8
17 P28700	   PAp01456379	   K	   HICAICGDR	   S	   9 0.08 0 0.26 0.57 0.15 -­‐0.88 2 2 2 9 2 6 7 17
20 P28700	   	  	   R	   EAVQEER	   Q	   7 0.04 0.01 0.18 0.29 0 0.11 3 4 4 12 3 8 47 24
21 P28700	   PAp01926863	   K	   YPEQPGR	   F	   7 0.04 0.02 0.23 0.26 0 0.1 2 2 2 8 2 5 7 15
22 P28700	   	  	   K	   DCLIDK	   R	   6 0.04 0.01 0.24 0.16 0.04 -­‐0.31 2 2 2 9 2 6 7 17
24 P28700	   	  	   R	   DMQMDK	   T	   6 0.03 0 0.09 0.09 0.02 0.04 2 2 2 8 2 5 7 15
25 P28700	   	  	   K	   CLAMGMK	   R	   7 0.03 0 0.36 0.13 0.01 -­‐0.32 1 1 1 4 1 3 4 8
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1 Q62432	   PAp00497924	  R	   VGETFHASQPSLTVDGFTDPSNSER	   F	   25 0.94 0.94 0.51 0.7 0.19 0.7 1 2 2 4 1 2 8 8 490670 2 1
12 Q62432	   PAp00501298	  R	   YGWHPATVCK	   I	   10 0.08 0.11 0.21 0.6 0.05 -­‐0.34 2 3 3 5 2 4 18 12 199240 4 3
3 Q62432	   PAp00385650	  R	   VETPVLPPVLVPR	   H	   13 0.85 0.79 0.52 0.58 0.06 0.56 3 4 4 9 3 8 24 21 8815200 1 1
8 Q62432	   PAp00002343	  R	   FCLGLLSNVNR	   N	   11 0.14 0.03 0.28 0.77 0.14 -­‐0.39 5 6 6 13 5 13 37 32 2
16 Q62432	   PAp00528190	  K	   GWGAEYR	   R	   7 0.05 0.05 0.21 0.36 0.04 0.03 2 3 3 5 2 4 18 12 367170 3
2 Q62432	   PAp00495033	  K	   SAGGSGGAGGGEQNGQEEK	   W	   19 0.89 0.91 0.34 0.79 0.03 0.49 1 2 2 6 1 2 8 10
4 Q62432	   	  	   -­‐	   MSSILPFTPPVVK	   R	   13 0.58 0.62 0.55 0.43 0.02 0.47 1 2 2 6 1 2 8 10
5 Q62432	   	  	   K	   AIENCEYAFNLK	   K	   12 0.57 0.61 0.41 0.51 0.07 -­‐0.21 1 2 2 6 1 2 9 10
6 Q62432	   PAp01525585	  K	   DEVCVNPYHYQR	   V	   12 0.36 0.41 0.19 0.46 0.13 -­‐0.38 2 3 3 9 2 7 17 19
7 Q62432	   PAp00472797	  R	   WPDLHSHHELK	   A	   11 0.22 0.37 0.19 0.31 0.06 0.3 1 2 2 6 1 2 9 10
9 Q62432	   PAp00432160	  K	   GLPHVIYCR	   L	   9 0.1 0.07 0.32 0.65 0.08 -­‐0.39 5 6 6 17 5 16 39 39
10 Q62432	   PAp00149351	  K	   VLTQMGSPSVR	   C	   11 0.09 0.03 0.92 0.55 0.03 0.27 1 2 2 3 1 2 7 7
11 Q62432	   PAp00395597	  K	   IFNNQEFAALLAQSVNQGFEAVYQLTR	   M	   27 0.09 0.08 0.04 0.75 0.01 0.12 2 3 3 5 2 4 18 12
13 Q62432	   	  	   R	   NATVEMTR	   R	   8 0.07 0.06 0.53 0.6 0 0.13 1 2 2 4 1 2 8 8
14 Q62432	   	  	   R	   QTVTSTPCWIELHLNGPLQWLDK	   V	   23 0.07 0.11 0.06 0.65 0.02 -­‐0.29 2 3 3 4 2 4 17 11
15 Q62432	   PAp01051569	  K	   AITTQNCNTK	   C	   10 0.06 0 0.28 0.6 0.04 -­‐0.23 1 2 2 6 1 2 8 10
17 Q62432	   	  	   K	   IPPGCNLK	   I	   8 0.05 0.01 0.5 0.32 0.04 -­‐0.12 2 3 3 5 2 4 18 12
18 Q62432	   	  	   R	   LDELEK	   A	   6 0.04 0.01 0.22 0.1 0.04 0.26 5 6 6 12 5 8 57 26
19 Q62432	   	  	   K	   CVTIPSTCSEIWGLSTANTVDQWDTTGLYSFSEQTR	   S	   36 0.04 0 0.07 0.63 0 -­‐0.66 1 1 1 3 1 1 0 5
20 Q62432	   	  	   R	   LYYIGGEVFAECLSDSAIFVQSPNCNQR	   Y	   28 0.04 0 0.02 0.59 0 -­‐0.86 2 3 3 5 2 4 18 12
21 Q62432	   	  	   R	   LQVSHR	   K	   6 0.03 0.01 0.07 0.12 0.01 -­‐0.11 5 6 6 17 5 16 42 39
Proteotypic	  peptides PeptideAtlas	  Predictions
Smad2_Q62432	  
Supplementary	  Data	  2:	  precursor-­‐	  to	  product-­‐ion	  transitions	  selected	  for	  SRM	  	  (10	  TFs)
Transcription	  Factor Sequence Parent	  ion	  mass Product	  ion	  mass Transition
m/z	  [M+2H]2+ m/z	  [M+H]+ y-­‐ion
ARID GGVSSIGTNTTTGSR 697.8471 319.1719 y3
ARID GGVSSIGTNTTTGSR 697.8471 420.2196 y4
ARID GGVSSIGTNTTTGSR 697.8471 521.2673 y5
ARID GGVSSIGTNTTTGSR 697.8471 622.3149 y6
ARID GGVSSIGTNTTTGSR 697.8471 736.3578 y7
ARID GGVSSIGTNTTTGSR 697.8471 837.4055 y8
ARID GGVSSIGTNTTTGSR 697.8471 894.427 y9
ARID GGVSSIGTNTTTGSR 697.8471 1007.511 y10
ARID GGVSSIGTNTTTGSR 697.8471 1094.543 y11
ARID GGVSSIGTNTTTGSR 697.8471 1181.575 y12
ARID GGVSSIGTNTTTGSR 697.8471 1280.644 y13
ARID GGVSSIGTNTTTGSR 697.8471 1337.665 y14
ARID GGVSSIGTNTTTGSR[HeavyR] 702.8512 329.1802 y3
ARID GGVSSIGTNTTTGSR[HeavyR] 702.8512 430.2278 y4
ARID GGVSSIGTNTTTGSR[HeavyR] 702.8512 531.2755 y5
ARID GGVSSIGTNTTTGSR[HeavyR] 702.8512 632.3232 y6
ARID GGVSSIGTNTTTGSR[HeavyR] 702.8512 746.3661 y7
ARID GGVSSIGTNTTTGSR[HeavyR] 702.8512 847.4138 y8
ARID GGVSSIGTNTTTGSR[HeavyR] 702.8512 904.4352 y9
ARID GGVSSIGTNTTTGSR[HeavyR] 702.8512 1017.519 y10
ARID GGVSSIGTNTTTGSR[HeavyR] 702.8512 1104.551 y11
ARID GGVSSIGTNTTTGSR[HeavyR] 702.8512 1191.583 y12
ARID GGVSSIGTNTTTGSR[HeavyR] 702.8512 1290.652 y13
ARID GGVSSIGTNTTTGSR[HeavyR] 702.8512 1347.673 y14
ARID GLNLPTSITSAAFTLR 831.4646 389.2502 y3
ARID GLNLPTSITSAAFTLR 831.4646 536.3185 y4
ARID GLNLPTSITSAAFTLR 831.4646 607.3557 y5
ARID GLNLPTSITSAAFTLR 831.4646 678.3928 y6
ARID GLNLPTSITSAAFTLR 831.4646 765.4248 y7
ARID GLNLPTSITSAAFTLR 831.4646 866.4725 y8
ARID GLNLPTSITSAAFTLR 831.4646 979.5566 y9
ARID GLNLPTSITSAAFTLR 831.4646 1066.589 y10
ARID GLNLPTSITSAAFTLR 831.4646 1167.636 y11
ARID GLNLPTSITSAAFTLR 831.4646 1264.689 y12
ARID GLNLPTSITSAAFTLR 831.4646 1377.773 y13
ARID GLNLPTSITSAAFTLR 831.4646 1491.816 y14
ARID GLNLPTSITSAAFTLR[HeavyR] 836.4688 399.2584 y3
ARID GLNLPTSITSAAFTLR[HeavyR] 836.4688 546.3268 y4
ARID GLNLPTSITSAAFTLR[HeavyR] 836.4688 617.364 y5
ARID GLNLPTSITSAAFTLR[HeavyR] 836.4688 688.4011 y6
ARID GLNLPTSITSAAFTLR[HeavyR] 836.4688 775.4331 y7
ARID GLNLPTSITSAAFTLR[HeavyR] 836.4688 876.4808 y8
ARID GLNLPTSITSAAFTLR[HeavyR] 836.4688 989.5648 y9
ARID GLNLPTSITSAAFTLR[HeavyR] 836.4688 1076.597 y10
ARID GLNLPTSITSAAFTLR[HeavyR] 836.4688 1177.645 y11
ARID GLNLPTSITSAAFTLR[HeavyR] 836.4688 1274.697 y12
ARID GLNLPTSITSAAFTLR[HeavyR] 836.4688 1387.781 y13
ARID GLNLPTSITSAAFTLR[HeavyR] 836.4688 1501.824 y14
Transcription	  Factor Sequence Parent	  ion	  mass Product	  ion	  mass Transition
m/z	  [M+2H]2+ m/z	  [M+H]+ y-­‐ion
FOSL2 GTGSAVGPVVVK 535.8138 345.2491 y3
FOSL2 GTGSAVGPVVVK 535.8138 444.3175 y4
FOSL2 GTGSAVGPVVVK 535.8138 541.3702 y5
FOSL2 GTGSAVGPVVVK 535.8138 598.3917 y6
FOSL2 GTGSAVGPVVVK 535.8138 697.4601 y7
FOSL2 GTGSAVGPVVVK 535.8138 768.4973 y8
FOSL2 GTGSAVGPVVVK 535.8138 855.5293 y9
FOSL2 GTGSAVGPVVVK 535.8138 912.5507 y10
FOSL2 GTGSAVGPVVVK 535.8138 1013.598 y11
FOSL2 GTGSAVGPVVVK[HeavyK] 539.8209 353.2633 y3
FOSL2 GTGSAVGPVVVK[HeavyK] 539.8209 452.3317 y4
FOSL2 GTGSAVGPVVVK[HeavyK] 539.8209 549.3845 y5
FOSL2 GTGSAVGPVVVK[HeavyK] 539.8209 606.4059 y6
FOSL2 GTGSAVGPVVVK[HeavyK] 539.8209 705.4744 y7
FOSL2 GTGSAVGPVVVK[HeavyK] 539.8209 776.5115 y8
FOSL2 GTGSAVGPVVVK[HeavyK] 539.8209 863.5435 y9
FOSL2 GTGSAVGPVVVK[HeavyK] 539.8209 920.5649 y10
FOSL2 GTGSAVGPVVVK[HeavyK] 539.8209 1021.613 y11
FOSL2 LQAETEELEEEK 724.3435 405.1974 y3
FOSL2 LQAETEELEEEK 724.3435 534.2401 y4
FOSL2 LQAETEELEEEK 724.3435 647.3241 y5
FOSL2 LQAETEELEEEK 724.3435 776.3667 y6
FOSL2 LQAETEELEEEK 724.3435 905.4093 y7
FOSL2 LQAETEELEEEK 724.3435 1006.457 y8
FOSL2 LQAETEELEEEK 724.3435 1135.5 y9
FOSL2 LQAETEELEEEK 724.3435 1206.537 y10
FOSL2 LQAETEELEEEK 724.3435 1334.595 y11
FOSL2 LQAETEELEEEK[HeavyK] 728.3506 413.2116 y3
FOSL2 LQAETEELEEEK[HeavyK] 728.3506 542.2542 y4
FOSL2 LQAETEELEEEK[HeavyK] 728.3506 655.3383 y5
FOSL2 LQAETEELEEEK[HeavyK] 728.3506 784.3809 y6
FOSL2 LQAETEELEEEK[HeavyK] 728.3506 913.4235 y7
FOSL2 LQAETEELEEEK[HeavyK] 728.3506 1014.471 y8
FOSL2 LQAETEELEEEK[HeavyK] 728.3506 1143.514 y9
FOSL2 LQAETEELEEEK[HeavyK] 728.3506 1214.551 y10
FOSL2 LQAETEELEEEK[HeavyK] 728.3506 1342.609 y11
Transcription	  Factor Sequence Parent	  ion	  mass Product	  ion	  mass Transition
m/z	  [M+2H]2+ m/z	  [M+H]+ y-­‐ion
NFIB EDFVLTVTGK 554.7978 305.1814 y3
NFIB EDFVLTVTGK 554.7978 404.2498 y4
NFIB EDFVLTVTGK 554.7978 505.2975 y5
NFIB EDFVLTVTGK 554.7978 618.3815 y6
NFIB EDFVLTVTGK 554.7978 717.45 y7
NFIB EDFVLTVTGK 554.7978 864.5184 y8
NFIB EDFVLTVTGK 554.7978 979.5453 y9
NFIB EDFVLTVTGK[HeavyK] 558.8049 313.1956 y3
NFIB EDFVLTVTGK[HeavyK] 558.8049 412.264 y4
NFIB EDFVLTVTGK[HeavyK] 558.8049 513.3117 y5
NFIB EDFVLTVTGK[HeavyK] 558.8049 626.3958 y6
NFIB EDFVLTVTGK[HeavyK] 558.8049 725.4642 y7
NFIB EDFVLTVTGK[HeavyK] 558.8049 872.5326 y8
NFIB EDFVLTVTGK[HeavyK] 558.8049 987.5595 y9
NFIB GIPLESTDGER 587.2909 304.161 y2
NFIB GIPLESTDGER 587.2909 361.1825 y3
NFIB GIPLESTDGER 587.2909 476.2094 y4
NFIB GIPLESTDGER 587.2909 577.2571 y5
NFIB GIPLESTDGER 587.2909 664.2891 y6
NFIB GIPLESTDGER 587.2909 793.3317 y7
NFIB GIPLESTDGER 587.2909 906.4158 y8
NFIB GIPLESTDGER 587.2909 1003.469 y9
NFIB GIPLESTDGER[HeavyR] 592.295 314.1693 y2
NFIB GIPLESTDGER[HeavyR] 592.295 371.1907 y3
NFIB GIPLESTDGER[HeavyR] 592.295 486.2177 y4
NFIB GIPLESTDGER[HeavyR] 592.295 587.2654 y5
NFIB GIPLESTDGER[HeavyR] 592.295 674.2974 y6
NFIB GIPLESTDGER[HeavyR] 592.295 803.34 y7
NFIB GIPLESTDGER[HeavyR] 592.295 916.424 y8
NFIB GIPLESTDGER[HeavyR] 592.295 1013.477 y9
Transcription	  Factor Sequence Parent	  ion	  mass Product	  ion	  mass Transition
m/z	  [M+2H]2+ m/z	  [M+H]+ y-­‐ion
NR2C1 AYVEFQDYITR 702.8433 389.2502 y3
NR2C1 AYVEFQDYITR 702.8433 552.3135 y4
NR2C1 AYVEFQDYITR 702.8433 667.3404 y5
NR2C1 AYVEFQDYITR 702.8433 795.399 y6
NR2C1 AYVEFQDYITR 702.8433 942.4674 y7
NR2C1 AYVEFQDYITR 702.8433 1071.51 y8
NR2C1 AYVEFQDYITR 702.8433 1170.578 y9
NR2C1 AYVEFQDYITR 702.8433 1333.642 y10
NR2C1 AYVEFQDYITR[HeavyR] 707.8474 399.2584 y3
NR2C1 AYVEFQDYITR[HeavyR] 707.8474 562.3217 y4
NR2C1 AYVEFQDYITR[HeavyR] 707.8474 677.3487 y5
NR2C1 AYVEFQDYITR[HeavyR] 707.8474 805.4073 y6
NR2C1 AYVEFQDYITR[HeavyR] 707.8474 952.4757 y7
NR2C1 AYVEFQDYITR[HeavyR] 707.8474 1081.518 y8
NR2C1 AYVEFQDYITR[HeavyR] 707.8474 1180.587 y9
NR2C1 AYVEFQDYITR[HeavyR] 707.8474 1343.65 y10
NR2C1 SPLAATPTFVTDSETAR 882.4441 347.2032 y3
NR2C1 SPLAATPTFVTDSETAR 882.4441 476.2458 y4
NR2C1 SPLAATPTFVTDSETAR 882.4441 563.2778 y5
NR2C1 SPLAATPTFVTDSETAR 882.4441 678.3047 y6
NR2C1 SPLAATPTFVTDSETAR 882.4441 779.3524 y7
NR2C1 SPLAATPTFVTDSETAR 882.4441 878.4208 y8
NR2C1 SPLAATPTFVTDSETAR 882.4441 1223.59 y11
NR2C1 SPLAATPTFVTDSETAR 882.4441 1395.675 y13
NR2C1 SPLAATPTFVTDSETAR[HeavyR] 887.4482 573.2861 y5
NR2C1 SPLAATPTFVTDSETAR[HeavyR] 887.4482 789.3607 y7
NR2C1 SPLAATPTFVTDSETAR[HeavyR] 887.4482 888.4291 y8
NR2C1 SPLAATPTFVTDSETAR[HeavyR] 887.4482 1136.545 y10
NR2C1 SPLAATPTFVTDSETAR[HeavyR] 887.4482 1233.598 y11
NR2C1 SPLAATPTFVTDSETAR[HeavyR] 887.4482 1334.646 y12
NR2C1 SPLAATPTFVTDSETAR[HeavyR] 887.4482 1405.683 y13
NR2C1 SPLAATPTFVTDSETAR[HeavyR] 887.4482 1476.72 y14
Transcription	  Factor Sequence Parent	  ion	  mass Product	  ion	  mass Transition
m/z	  [M+2H]2+ m/z	  [M+H]+ y-­‐ion
PIAS3 VSSIVAPGSSLR 586.8353 375.2345 y3
PIAS3 VSSIVAPGSSLR 586.8353 462.2665 y4
PIAS3 VSSIVAPGSSLR 586.8353 519.288 y5
PIAS3 VSSIVAPGSSLR 586.8353 616.3408 y6
PIAS3 VSSIVAPGSSLR 586.8353 687.3779 y7
PIAS3 VSSIVAPGSSLR 586.8353 786.4463 y8
PIAS3 VSSIVAPGSSLR 586.8353 899.5303 y9
PIAS3 VSSIVAPGSSLR 586.8353 986.5624 y10
PIAS3 VSSIVAPGSSLR 586.8353 1073.594 y11
PIAS3 VSSIVAPGSSLR[HeavyR] 591.8394 385.2428 y3
PIAS3 VSSIVAPGSSLR[HeavyR] 591.8394 472.2748 y4
PIAS3 VSSIVAPGSSLR[HeavyR] 591.8394 529.2963 y5
PIAS3 VSSIVAPGSSLR[HeavyR] 591.8394 626.349 y6
PIAS3 VSSIVAPGSSLR[HeavyR] 591.8394 697.3861 y7
PIAS3 VSSIVAPGSSLR[HeavyR] 591.8394 796.4545 y8
PIAS3 VSSIVAPGSSLR[HeavyR] 591.8394 909.5386 y9
PIAS3 VSSIVAPGSSLR[HeavyR] 591.8394 996.5706 y10
PIAS3 VSSIVAPGSSLR[HeavyR] 591.8394 1083.603 y11
PIAS3 VSELQVLLGFAGR 694.8984 303.177 y3
PIAS3 VSELQVLLGFAGR 694.8984 450.2454 y4
PIAS3 VSELQVLLGFAGR 694.8984 507.2668 y5
PIAS3 VSELQVLLGFAGR 694.8984 620.351 y6
PIAS3 VSELQVLLGFAGR 694.8984 733.435 y7
PIAS3 VSELQVLLGFAGR 694.8984 832.5034 y8
PIAS3 VSELQVLLGFAGR 694.8984 960.562 y9
PIAS3 VSELQVLLGFAGR 694.8984 1073.646 y10
PIAS3 VSELQVLLGFAGR 694.8984 1202.689 y11
PIAS3 VSELQVLLGFAGR 694.8984 1289.721 y12
PIAS3 VSELQVLLGFAGR[HeavyR] 699.9025 313.1852 y3
PIAS3 VSELQVLLGFAGR[HeavyR] 699.9025 460.2537 y4
PIAS3 VSELQVLLGFAGR[HeavyR] 699.9025 517.2751 y5
PIAS3 VSELQVLLGFAGR[HeavyR] 699.9025 630.3592 y6
PIAS3 VSELQVLLGFAGR[HeavyR] 699.9025 743.4432 y7
PIAS3 VSELQVLLGFAGR[HeavyR] 699.9025 842.5117 y8
PIAS3 VSELQVLLGFAGR[HeavyR] 699.9025 970.5703 y9
PIAS3 VSELQVLLGFAGR[HeavyR] 699.9025 1083.654 y10
PIAS3 VSELQVLLGFAGR[HeavyR] 699.9025 1212.697 y11
PIAS3 VSELQVLLGFAGR[HeavyR] 699.9025 1299.729 y12
Transcription	  Factor Sequence Parent	  ion	  mass Product	  ion	  mass Transition
m/z	  [M+2H]2+ m/z	  [M+H]+ y-­‐ion
PIAS4 SYSVALYLVR 585.8295 387.2709 y3
PIAS4 SYSVALYLVR 585.8295 550.3342 y4
PIAS4 SYSVALYLVR 585.8295 663.4183 y5
PIAS4 SYSVALYLVR 585.8295 734.4554 y6
PIAS4 SYSVALYLVR 585.8295 833.5238 y7
PIAS4 SYSVALYLVR 585.8295 920.5558 y8
PIAS4 SYSVALYLVR 585.8295 1083.619 y9
PIAS4 SYSVALYLVR[HeavyR] 590.8336 397.2791 y3
PIAS4 SYSVALYLVR[HeavyR] 590.8336 560.3425 y4
PIAS4 SYSVALYLVR[HeavyR] 590.8336 673.4265 y5
PIAS4 SYSVALYLVR[HeavyR] 590.8336 744.4637 y6
PIAS4 SYSVALYLVR[HeavyR] 590.8336 843.532 y7
PIAS4 SYSVALYLVR[HeavyR] 590.8336 930.5641 y8
PIAS4 SYSVALYLVR[HeavyR] 590.8336 1093.627 y9
PIAS4 LDPDSEIATTGVR 687.3489 331.2083 y3
PIAS4 LDPDSEIATTGVR 687.3489 432.256 y4
PIAS4 LDPDSEIATTGVR 687.3489 533.3036 y5
PIAS4 LDPDSEIATTGVR 687.3489 604.3408 y6
PIAS4 LDPDSEIATTGVR 687.3489 717.4248 y7
PIAS4 LDPDSEIATTGVR 687.3489 846.4674 y8
PIAS4 LDPDSEIATTGVR 687.3489 933.4995 y9
PIAS4 LDPDSEIATTGVR 687.3489 1048.526 y10
PIAS4 LDPDSEIATTGVR 687.3489 1145.579 y11
PIAS4 LDPDSEIATTGVR 687.3489 1260.606 y12
PIAS4 LDPDSEIATTGVR[HeavyR] 692.3531 341.2166 y3
PIAS4 LDPDSEIATTGVR[HeavyR] 692.3531 442.2642 y4
PIAS4 LDPDSEIATTGVR[HeavyR] 692.3531 543.3119 y5
PIAS4 LDPDSEIATTGVR[HeavyR] 692.3531 614.349 y6
PIAS4 LDPDSEIATTGVR[HeavyR] 692.3531 727.4331 y7
PIAS4 LDPDSEIATTGVR[HeavyR] 692.3531 856.4757 y8
PIAS4 LDPDSEIATTGVR[HeavyR] 692.3531 943.5077 y9
PIAS4 LDPDSEIATTGVR[HeavyR] 692.3531 1058.535 y10
PIAS4 LDPDSEIATTGVR[HeavyR] 692.3531 1155.587 y11
PIAS4 LDPDSEIATTGVR[HeavyR] 692.3531 1270.614 y12
Transcription	  Factor Sequence Parent	  ion	  mass Product	  ion	  mass Transition
m/z	  [M+2H]2+ m/z	  [M+H]+ y-­‐ion
PPARγ HLYDSYIK 519.7663 423.2596 y3
PPARγ HLYDSYIK 519.7663 510.2917 y4
PPARγ HLYDSYIK 519.7663 625.3186 y5
PPARγ HLYDSYIK 519.7663 788.382 y6
PPARγ HLYDSYIK[HeavyK] 523.7734 431.2738 y3
PPARγ HLYDSYIK[HeavyK] 523.7734 518.3058 y4
PPARγ HLYDSYIK[HeavyK] 523.7734 633.3328 y5
PPARγ HLYDSYIK[HeavyK] 523.7734 796.3961 y6
PPARγ VEPASPPYYSEK 683.8298 363.1869 y3
PPARγ VEPASPPYYSEK 683.8298 526.2502 y4
PPARγ VEPASPPYYSEK 683.8298 689.3135 y5
PPARγ VEPASPPYYSEK 683.8298 786.3663 y6
PPARγ VEPASPPYYSEK 683.8298 883.4191 y7
PPARγ VEPASPPYYSEK 683.8298 970.4511 y8
PPARγ VEPASPPYYSEK 683.8298 1041.488 y9
PPARγ VEPASPPYYSEK 683.8298 1138.541 y10
PPARγ LNHPESSQLFAK 685.8567 365.2178 y3
PPARγ LNHPESSQLFAK 685.8567 478.3018 y4
PPARγ LNHPESSQLFAK 685.8567 606.3604 y5
PPARγ LNHPESSQLFAK 685.8567 693.3925 y6
PPARγ LNHPESSQLFAK 685.8567 780.4245 y7
PPARγ LNHPESSQLFAK 685.8567 909.4671 y8
PPARγ LNHPESSQLFAK 685.8567 1006.52 y9
PPARγ LNHPESSQLFAK 685.8567 1143.579 y10
PPARγ VEPASPPYYSEK[HeavyK] 687.8369 371.2011 y3
PPARγ VEPASPPYYSEK[HeavyK] 687.8369 534.2644 y4
PPARγ VEPASPPYYSEK[HeavyK] 687.8369 697.3278 y5
PPARγ VEPASPPYYSEK[HeavyK] 687.8369 794.3805 y6
PPARγ VEPASPPYYSEK[HeavyK] 687.8369 891.4333 y7
PPARγ VEPASPPYYSEK[HeavyK] 687.8369 978.4653 y8
PPARγ VEPASPPYYSEK[HeavyK] 687.8369 1049.502 y9
PPARγ VEPASPPYYSEK[HeavyK] 687.8369 1146.555 y10
PPARγ LNHPESSQLFAK[HeavyK] 689.8638 373.232 y3
PPARγ LNHPESSQLFAK[HeavyK] 689.8638 486.316 y4
PPARγ LNHPESSQLFAK[HeavyK] 689.8638 614.3746 y5
PPARγ LNHPESSQLFAK[HeavyK] 689.8638 701.4067 y6
PPARγ LNHPESSQLFAK[HeavyK] 689.8638 788.4387 y7
PPARγ LNHPESSQLFAK[HeavyK] 689.8638 917.4813 y8
PPARγ LNHPESSQLFAK[HeavyK] 689.8638 1014.534 y9
PPARγ LNHPESSQLFAK[HeavyK] 689.8638 1151.593 y10
PPARγ SVEAVQEITEYAK 733.8722 381.2127 y3
PPARγ SVEAVQEITEYAK 733.8722 510.2553 y4
PPARγ SVEAVQEITEYAK 733.8722 611.303 y5
PPARγ SVEAVQEITEYAK 733.8722 724.387 y6
PPARγ SVEAVQEITEYAK 733.8722 853.4296 y7
PPARγ SVEAVQEITEYAK 733.8722 981.4882 y8
PPARγ SVEAVQEITEYAK 733.8722 1080.557 y9
PPARγ SVEAVQEITEYAK 733.8722 1151.594 y10
PPARγ SVEAVQEITEYAK 733.8722 1280.636 y11
PPARγ SVEAVQEITEYAK[HeavyK] 737.8793 389.2269 y3
PPARγ SVEAVQEITEYAK[HeavyK] 737.8793 518.2695 y4
PPARγ SVEAVQEITEYAK[HeavyK] 737.8793 619.3171 y5
PPARγ SVEAVQEITEYAK[HeavyK] 737.8793 732.4012 y6
PPARγ SVEAVQEITEYAK[HeavyK] 737.8793 861.4438 y7
PPARγ SVEAVQEITEYAK[HeavyK] 737.8793 989.5024 y8
PPARγ SVEAVQEITEYAK[HeavyK] 737.8793 1088.571 y9
PPARγ SVEAVQEITEYAK[HeavyK] 737.8793 1159.608 y10
PPARγ SVEAVQEITEYAK[HeavyK] 737.8793 1288.651 y11
Transcription	  Factor Sequence Parent	  ion	  mass Product	  ion	  mass Transition
m/z	  [M+2H]2+ m/z	  [M+H]+ y-­‐ion
RARG GLGQPDLPK 462.761 357.2491 y3
RARG GLGQPDLPK 462.761 472.276 y4
RARG GLGQPDLPK 462.761 569.3288 y5
RARG GLGQPDLPK 462.761 697.3874 y6
RARG GLGQPDLPK 462.761 754.4088 y7
RARG GLGQPDLPK 462.761 867.4929 y8
RARG GLGQPDLPK[HeavyK] 466.7681 365.2633 y3
RARG GLGQPDLPK[HeavyK] 466.7681 480.2902 y4
RARG GLGQPDLPK[HeavyK] 466.7681 577.343 y5
RARG GLGQPDLPK[HeavyK] 466.7681 705.4016 y6
RARG GLGQPDLPK[HeavyK] 466.7681 762.423 y7
RARG GLGQPDLPK[HeavyK] 466.7681 875.5071 y8
RARG LQEPLLEALR 591.348 359.2396 y3
RARG LQEPLLEALR 591.348 488.2822 y4
RARG LQEPLLEALR 591.348 601.3662 y5
RARG LQEPLLEALR 591.348 714.4503 y6
RARG LQEPLLEALR 591.348 811.5031 y7
RARG LQEPLLEALR 591.348 940.5457 y8
RARG LQEPLLEALR 591.348 1068.604 y9
RARG VQLDLGLWDK 593.8269 448.2185 y3
RARG VQLDLGLWDK 593.8269 561.3026 y4
RARG VQLDLGLWDK 593.8269 618.324 y5
RARG VQLDLGLWDK 593.8269 731.4081 y6
RARG VQLDLGLWDK 593.8269 846.4351 y7
RARG VQLDLGLWDK 593.8269 959.5191 y8
RARG VQLDLGLWDK 593.8269 1087.578 y9
RARG LQEPLLEALR[HeavyR] 596.3521 369.2479 y3
RARG LQEPLLEALR[HeavyR] 596.3521 498.2904 y4
RARG LQEPLLEALR[HeavyR] 596.3521 611.3745 y5
RARG LQEPLLEALR[HeavyR] 596.3521 724.4586 y6
RARG LQEPLLEALR[HeavyR] 596.3521 821.5114 y7
RARG LQEPLLEALR[HeavyR] 596.3521 950.554 y8
RARG LQEPLLEALR[HeavyR] 596.3521 1078.613 y9
RARG VQLDLGLWDK[HeavyK] 597.834 456.2327 y3
RARG VQLDLGLWDK[HeavyK] 597.834 569.3168 y4
RARG VQLDLGLWDK[HeavyK] 597.834 626.3383 y5
RARG VQLDLGLWDK[HeavyK] 597.834 739.4223 y6
RARG VQLDLGLWDK[HeavyK] 597.834 854.4492 y7
RARG VQLDLGLWDK[HeavyK] 597.834 967.5333 y8
RARG VQLDLGLWDK[HeavyK] 597.834 1095.592 y9
Transcription	  Factor Sequence Parent	  ion	  mass Product	  ion	  mass Transition
m/z	  [M+2H]2+ m/z	  [M+H]+ y-­‐ion
RXRα VLTELVSK 444.7736 333.2127 y3
RXRα VLTELVSK 444.7736 446.2968 y4
RXRα VLTELVSK 444.7736 575.3394 y5
RXRα VLTELVSK 444.7736 676.387 y6
RXRα VLTELVSK 444.7736 789.4711 y7
RXRα VLTELVSK[HeavyK] 448.7807 341.2269 y3
RXRα VLTELVSK[HeavyK] 448.7807 454.311 y4
RXRα VLTELVSK[HeavyK] 448.7807 583.3536 y5
RXRα VLTELVSK[HeavyK] 448.7807 684.4012 y6
RXRα VLTELVSK[HeavyK] 448.7807 797.4853 y7
RXRα AIVLFNPDSK 552.3084 349.1712 y3
RXRα AIVLFNPDSK 552.3084 446.224 y4
RXRα AIVLFNPDSK 552.3084 560.2669 y5
RXRα AIVLFNPDSK 552.3084 707.3353 y6
RXRα AIVLFNPDSK 552.3084 820.4194 y7
RXRα AIVLFNPDSK 552.3084 919.4878 y8
RXRα AIVLFNPDSK 552.3084 1032.572 y9
RXRα AIVLFNPDSK[HeavyK] 556.3155 357.1854 y3
RXRα AIVLFNPDSK[HeavyK] 556.3155 454.2382 y4
RXRα AIVLFNPDSK[HeavyK] 556.3155 568.2811 y5
RXRα AIVLFNPDSK[HeavyK] 556.3155 715.3495 y6
RXRα AIVLFNPDSK[HeavyK] 556.3155 828.4336 y7
RXRα AIVLFNPDSK[HeavyK] 556.3155 927.502 y8
RXRα AIVLFNPDSK[HeavyK] 556.3155 1040.586 y9
RXRα ILEAELAVEPK 606.3477 373.2076 y3
RXRα ILEAELAVEPK 606.3477 472.276 y4
RXRα ILEAELAVEPK 606.3477 543.3131 y5
RXRα ILEAELAVEPK 606.3477 656.3972 y6
RXRα ILEAELAVEPK 606.3477 785.4398 y7
RXRα ILEAELAVEPK 606.3477 856.4769 y8
RXRα ILEAELAVEPK 606.3477 985.5195 y9
RXRα ILEAELAVEPK 606.3477 1098.604 y10
RXRα ILEAELAVEPK[HeavyK] 610.3548 381.2218 y3
RXRα ILEAELAVEPK[HeavyK] 610.3548 480.2902 y4
RXRα ILEAELAVEPK[HeavyK] 610.3548 551.3273 y5
RXRα ILEAELAVEPK[HeavyK] 610.3548 664.4114 y6
RXRα ILEAELAVEPK[HeavyK] 610.3548 793.454 y7
RXRα ILEAELAVEPK[HeavyK] 610.3548 864.4911 y8
RXRα ILEAELAVEPK[HeavyK] 610.3548 993.5337 y9
RXRα ILEAELAVEPK[HeavyK] 610.3548 1106.618 y10
RXRα GLSNPAEVEALR 628.3356 359.2396 y3
RXRα GLSNPAEVEALR 628.3356 488.2822 y4
RXRα GLSNPAEVEALR 628.3356 587.3506 y5
RXRα GLSNPAEVEALR 628.3356 716.3932 y6
RXRα GLSNPAEVEALR 628.3356 787.4303 y7
RXRα GLSNPAEVEALR 628.3356 884.483 y8
RXRα GLSNPAEVEALR 628.3356 998.526 y9
RXRα GLSNPAEVEALR 628.3356 1085.558 y10
RXRα GLSNPAEVEALR 628.3356 1198.642 y11
RXRα GLSNPAEVEALR[HeavyR] 633.3398 369.2479 y3
RXRα GLSNPAEVEALR[HeavyR] 633.3398 498.2904 y4
RXRα GLSNPAEVEALR[HeavyR] 633.3398 597.3589 y5
RXRα GLSNPAEVEALR[HeavyR] 633.3398 726.4014 y6
RXRα GLSNPAEVEALR[HeavyR] 633.3398 797.4385 y7
RXRα GLSNPAEVEALR[HeavyR] 633.3398 894.4913 y8
RXRα GLSNPAEVEALR[HeavyR] 633.3398 1008.534 y9
RXRα GLSNPAEVEALR[HeavyR] 633.3398 1095.566 y10
RXRα GLSNPAEVEALR[HeavyR] 633.3398 1208.65 y11
Transcription	  Factor Sequence Parent	  ion	  mass Product	  ion	  mass Transition
m/z	  [M+2H]2+ m/z	  [M+H]+ y-­‐ion
SMAD2 GWGAEYR 419.6957 338.1817 y2
SMAD2 GWGAEYR 419.6957 467.2243 y3
SMAD2 GWGAEYR 419.6957 538.2614 y4
SMAD2 GWGAEYR 419.6957 595.2829 y5
SMAD2 GWGAEYR 419.6957 781.3622 y6
SMAD2 GWGAEYR[HeavyR] 424.6998 348.19 y2
SMAD2 GWGAEYR[HeavyR] 424.6998 477.2326 y3
SMAD2 GWGAEYR[HeavyR] 424.6998 548.2697 y4
SMAD2 GWGAEYR[HeavyR] 424.6998 605.2912 y5
SMAD2 GWGAEYR[HeavyR] 424.6998 791.3705 y6
SMAD2 VETPVLPPVLVPR 708.4346 371.2396 y3
SMAD2 VETPVLPPVLVPR 708.4346 583.392 y5
SMAD2 VETPVLPPVLVPR 708.4346 680.4448 y6
SMAD2 VETPVLPPVLVPR 708.4346 777.4976 y7
SMAD2 VETPVLPPVLVPR 708.4346 890.5817 y8
SMAD2 VETPVLPPVLVPR 708.4346 989.6501 y9
SMAD2 VETPVLPPVLVPR 708.4346 1086.703 y10
SMAD2 VETPVLPPVLVPR 708.4346 1187.75 y11
SMAD2 VETPVLPPVLVPR[HeavyR] 713.4388 381.2479 y3
SMAD2 VETPVLPPVLVPR[HeavyR] 713.4388 494.3319 y4
SMAD2 VETPVLPPVLVPR[HeavyR] 713.4388 593.4003 y5
SMAD2 VETPVLPPVLVPR[HeavyR] 713.4388 690.4531 y6
SMAD2 VETPVLPPVLVPR[HeavyR] 713.4388 787.5059 y7
SMAD2 VETPVLPPVLVPR[HeavyR] 713.4388 900.5899 y8
SMAD2 VETPVLPPVLVPR[HeavyR] 713.4388 999.6583 y9
SMAD2 VETPVLPPVLVPR[HeavyR] 713.4388 1096.711 y10
